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4AbSTrACT
Glucocorticoids (GC) have been used in a wide variety of inflammatory and immune 
conditions for over fifty years. In inflammatory bowel disease (IBD), ulcerative colitis 
(UC) and Crohn’s disease (CD), they are an essential component of the treatment of acute 
flare-ups of the disease. The care of children with IBD follows the same principles than 
that of adults. Upon disease activation, standard treatment strategy is to use doses of 
1-2 mg/kg/day of prednisone equivalents for 4-6 weeks and then taper. After 3 months, 
approximately 80% of the patients have responded positively to the therapy, however, 
the development of steroid dependency and resistance as well as treatment-induced 
side-effects are common. The aim of this study was to evaluate whether a new bioassay 
measuring GC bioactivity (GBA) directly from a small amount of patient serum could be 
used alone or in combination with GC-responsive biomarkers to optimize steroid therapy 
in paediatric IBD patients in such a way that the children would get the best possible 
benefit from the treatment with the least possible side-effects. 
Sixty-nine paediatric IBD patients from the Paediatric Outpatient Clinics of the University 
Hospitals of Helsinki and Tampere participated in the studies. Control patients included 41 
disease controls in remission and 101 non-IBD patients. Blood samples were withdrawn 
before the GC treatment was started, at 2-4 weeks after the onset of the steroid and at 1-month 
intervals thereafter. The development of GC-related side effects was carefully registered. 
GBA was measured with a COS-1 cell bioassay in which the cells were transfected with 
the GC receptor (GR) gene and the luciferase reporter gene. The cells were incubated 
with the patients’ 10 µl serum sample, and the relative luciferase activity was read from 
the standard curve. The GC-responsive biomarkers analyzed included adipocyte-derived 
adiponectin and leptin, bone turnover-related collagen markers amino-terminal type I 
procollagen propeptide (PINP) and carboxyterminal telopeptide of type I collagen (ICTP) 
as well as insulin-like growth factor 1 (IGF-1) and sex hormone binding globulin (SHBG), 
and inflammatory marker high-sensitivity C-reactive protein (hs-CRP).
In the first study, an upper limit for endogenous serum GBA (118 nM cortisol equivalents, 
mean + 2SD) was established by measuring GBA in the 142 control children. In patients 
treated with systemic GCs, serum GBA showed a 4-fold increase after two weeks of therapy. 
In contrast, in patients treated with budesonide, only a 1.8-fold increase was seen after 
four weeks of treatment. In all patients, the GBA levels remained above the upper limit for 
endogenous serum GBA until the withdrawal of the steroid. GBA levels in patients less than 
10 years of age were similar to the older patients, even though the young patients received 
higher weight-adjusted doses of prednisolone (1.3 vs. 0.79 mg/kg, P<0.05). The GBA levels 
were not related to the development of GC-related side-effects or to therapeutic response.
5In the second study, the changes in the GBA levels and adipose tissue-derived hormones 
leptin and adiponectin were evaluated during GC therapy. Steroid treatment induced 
serum adiponectin (from 11.9 ± 1.5 µg/ml to 18.7 ± 1.8 µg/ml) and leptin (from 4.4 ± 
0.9 µg/l to 7.7 ± 1.5 µg/l). Notably, after 2 to 4 weeks of therapy, the adiponectin levels 
were higher in 7 patients who developed acute GC-related side-effects (rounding of the 
cheeks) than in the 11 patients who did not (22.9 ± 2.6 µg/ml vs. 16.0 ± 2.1 µg/ml, 
P<0.05). Serum leptin levels indicated a similar trend. GBA levels were not related to 
adiponectin or leptin levels.
The third study examined GBA and bone turnover-related markers in children receiving 
systemic steroid therapy. Before GC treatment, PINP and IGF-1 levels were lower in 
children with active IBD compared with control children with IBD in remission. After 2 
weeks of steroid therapy, serum IGF-I had increased from 23 to 37 nmol/l (P<0.001). In 
contrast, serum PINP levels had further declined, from 271 µg/l to 163 µg/l (P<0.001), 
ICTP from 14.2 µg/l to 9.6 µg/l (P<0.001) and SHBG from 54 to 35 nmol/l (P<0.001), 
respectively. After the withdrawal of the GC, all bone markers restored to levels similar 
to the controls. Serum GBA, response to GC treatment or the appearance of GC-related 
side-effects did not correlate with the markers of bone metabolism.
Finally, in the fourth study, the levels of the inflammatory marker hs-CRP were evaluated 
during GC therapy and in patients undergoing colonoscopy. The median pre-treatment 
CRP level of the 22 IBD patients starting peroral GC therapy was 0.6 mg/L (0.01-39), 
which decreased to 0.08 mg/L (0.004-60, P<0.05) after 2-4 weeks of treatment. The hs-
CRP levels did not differ between patients that responded to steroid therapy and non-
responders. The development of GC-related side-effects did not associate with serum 
CRP. Hs-CRP was not able to distinguish the patients with different disease activities.
Based on these findings, it can be concluded that even though the GBA levels rose in 
paediatric IBD patients receiving systemic GC treatment, they did not associate with 
the clinical response to GCs or with GC-related side-effects. In the light of these results 
therefore, the GBA measurement cannot guide the GC therapy in these patients. Of the 
biomarkers investigated, adipocyte-derived adiponectin associated with GC therapy-
induced side-effects, and was the most promising marker of GC sensitivity. Markers of 
bone turnover and inflammation changed in response to the GC therapy; however, they 
did not correlate with the clinical response or GC therapy-related adverse events. 
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iNTrOdUCTiON
Glucocorticoids (GCs) are steroid hormones that originate from the adrenal cortex. The 
endogenous GCs, cortisone and corticosterone, are essential for life and have a large array 
of functions in the maintenance of body homeostasis during stress response, in protein, lipid 
and carbohydrate metabolism, and in the regulation of inflammatory and immune reactions. 
GCs exert their effects through binding to the intracellular glucocorticoid receptor (GR) that 
then affects the expression of GC-responsive genes by a number of different mechanisms.
Pharmacological GC therapy started with the successful treatment of rheumatoid 
arthritis in the 1940s, using cortisone acetate. Since then, the use of steroids has expanded, 
and today they form part of the treatment of various diseases in practically every organ 
system. In gastroenterology, inflammatory bowel disease is a central target.
Inflammatory bowel disease (IBD) encompassing Crohn’s disease (CD) and ulcerative 
colitis (CD) is a chronic, relapsing and remitting inflammatory disorder of the gastrointestinal 
tract. Its cause is not known, but the current view is that it results from an exaggerated and 
inappropriate immune response to environmental antigens in a genetically susceptible host. 
Approximately 20% of the cases manifest during childhood, and the disease has a profound 
effect on the physical and psychological development of the growing child. No cure exists, 
but with the aid of nutritional, pharmacological, surgical and psychological treatment and 
support the patients can be ensured an as near-to-normal life as possible.
In IBD, GCs come into play upon disease activation when the patient complains of 
frequent, often bloody diarrhea, abdominal pain, weight loss and fever. In children, active 
inflammation may associate with growth failure. The therapy is initiated with a daily dose of 
1-2 mg/kg of prednisone equivalents for 4-6 weeks and then tapered off in small steps. After 
three months, approximately 80% of the patients have obtained a positive clinical response. 
Unfortunately however, clinical improvement does not often associate with endoscopical 
and histological remission. In addition, the development of GC-related side-effects and 
steroid dependency and resistance are common.
In current clinical use, we do not have any assay or biomarker with which to predict 
the individual’s response to exogenous GC therapy in advance. This would be vital in order 
to save this effective but potentially toxic treatment for patients who could actually benefit 
from it. The aim of this study was to thus evaluate whether a new bioassay measuring 
circulating GC bioactivity (GBA) directly from a small amount of human serum could be 
used alone, or together with GC-responsive biomarkers, to improve the benefit-to-risk ratio 
of paediatric IBD patients receiving systemic GC therapy.
iNTrOdUCTiON
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review OF THe liTerATUre
1. Glucocorticoids – basic 
GCs are steroid hormones that are synthesized from cholesterol in the zona fasciculata 
of the adrenal cortex in a circadian and stress-related fashion. The name glucocorticoid 
originally refers to the actions these hormones have on glucose metabolism, however the 
effects of GCs are now known to be far more widespread and essential for life (Guyton and 
Hall 2006). In DNA microarray analysis, 20% of the expressed human leukocyte genome 
was found to be affected by GCs, and the current view is that GCs are involved in nearly 
every molecular, cellular and physiologic network of the organism (Chrousos and Kino 
2005).
1.1 Glucocorticoids
Cholesterol needed for steroid hormone synthesis derives mainly from circulating low-
density lipoproteins. They enter the adrenocortical cells through coated pits and liberate 
the cholesterol which is then transported to mitochondria and endoplasmic reticulum 
to be processed further (Guyton and Hall 2006). Specific enzymes guide every step of the 
pathway that in addition to GCs results in the synthesis of aldosterone and sex steroids 
(Figure 1). 
15review OF THe  liTerATUre
Figure 1 Steroid biosynthesis in the adrenal cortex (modified from Nimkarn et al. 2007)
The main endogenous GC hormone cortisol (hydrocortisone, Figure 2) accounts for 95 
per cent of the GC activity of the body. The rest of the activity is divided between the 
much less potent corticosterone (4 per cent) and the possible circulating synthetic GCs. 
Over 90 per cent of the circulating cortisol is bound to cortisol-binding globulin (CBG), 
and to a lesser extent and affinity to albumin. Plasma protein-bound steroids might serve 
as a reservoir to reduce the rapid fluctuations of free hormone concentrations that would 
occur for example during stress and episodic adrenocorticotropic hormone (ACTH) 
secretion (Guyton and Hall 2006). 
Figure 2 The structures of cortisol (a), prednisolone (b) and budesonide (c). Hydroxyl group at 
carbon 11 is necessary for the GH activity of the molecule. Therefore 11-keto compounds 
cortisone and prednisone need to be converted to their respective 11-hydroxyl counterparts 
to be operative (Axelrod 2003).
16
1.1.1 Cortisone-cortisol shuttle
11β-hydroxysteroid	 dehydrogenases	 (11β-HSDs)	 interconvert	 inactive	 cortisone	 and	
cortisol.	11β-HSD1	is	expressed	in	many	tissues	including	the	liver,	bone	and	adipose	
tissue	and	possesses	both	reductase	and	dehydrogenase	activities.	11β-HSD2,	in	contrast,	
is expressed in mineralocorticoid target tissues, predominantly in the kidney, and 
catalyzes the conversion of cortisol to cortisone (Tomlinson et al. 2004). These enzymes are now 
considered	to	be	significant	regulators	of	hormone	action	at	tissue	level.	Altered	11β-HSD1	
activity has been implicated in the metabolic syndrome and both enzymes in modulating 
the functions of the immune system (Cooper and Stewart 2009).	11β-HSD2	expression	has	been	
reported in the macrophages and synovial tissue of patients with rheumatoid arthritis, which 
might render these tissues less sensitive to GC therapy (Rabbitt et al. 2008, Haas et al. 2007). On 
the	contrary,	increased	11β-HSD1	and	decreased	11β-HSD2	expression	has	been	found	in	
both human patients with UC and rats with induced colitis (Žbánková	et	al.	2007).
1.1.2 Function in humans
GCs have effects on carbohydrate, protein and lipid metabolism of the organism, as well 
as on immune and inflammatory functions. In addition to the basal pulsatile circadian 
secretion, the main inducer of GC release from the adrenal cortex is stress, psychological 
or physical. Stress activates the hypothalamic-pituitary-adrenal (HPA) axis where the 
secretion of corticotropin-releasing hormone (CRH) from the hypothalamus activates 
ACTH secretion in the anterior pituitary. ACTH in turn increases the production and 
secretion of cortisol that exerts negative feedback at the brain, thus controlling its own 
secretion (Guyton and Hall 2006). 
The net effect of GCs on glucose metabolism is an increase of blood glucose 
concentration due to increased gluconeogenesis by the liver and decreased glucose 
utilization by most cells of the body. Cellular protein stores diminish, with the exception 
of liver whose intake of amino acids (aa) and protein synthesis increase. The mobilization 
of fatty acids from the adipose tissue also augments, and their elevated concentration in 
the plasma enhances their utilization for energy (Guyton and Hall 2006).
The use of GCs in immunological and inflammatory conditions is based on their 
anti-inflammatory properties. At cellular level, GCs stabilize lysosomal membranes, 
decrease the permeability of capillaries and reduce the migration of white blood cells into 
inflamed areas (Guyton and Hall 2006). At molecular level, they favour innate immunological 
responses and Th2-driven humoral immunity, and suppress Th1 cellular immunity 
(Franchimont 2004). 
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1.2 Glucocorticoid receptor
GCs exert their functions through the GC receptor (GR, NR3C1) that belongs to the superfamily 
of nuclear receptors (Mangelsdorf et al. 1995). Nuclear receptors are intracellular transcription 
factors that together with cognate ligands and other proteins regulate the expression of 
target genes. The members of the family bear functional and structural similarity, and GR 
belongs to the subfamily 3 together with receptors for estrogen, progesterone, androgen and 
mineralocorticoids (Nuclear Receptors Nomenclature Committee 1999). 
1.2.1 Glucocorticoid receptor gene
The human GR (hGR) gene is localized in the long arm of chromosome 5q31-32 (Francke 
and Foellmer 1989, Theriault et al. 1989). The gene has at least 13 different splice variants that 
derive from 9 different exon 1s (Figure 3). The transcripts contain 9 exons, the first 
of which is 5’ untranslated region (Figure 3) (Encío and Detera-Wadleigh 1991, Breslin et al. 
2001, Turner and Muller 2005, Presul et al. 2007). The alternative exon 1 variants are spliced 
to a common acceptor site at the beginning of exon 2, and do not alter the amino acid 
sequence of GR (McCormick et al. 2000, Turner and Muller 2005). However, the tissue expression 
profiles of the transcripts differ and it has been postulated that exon 1 variants with their 
own putative promoters might be a significant tissue, cell, and stimuli specific control 
mechanism of the transcription of hGR (Turner and Muller 2005, Turner et al. 2006).
Translation initiation codon is localized in exon 2. Exon 2 also contains the coding 
sequence for activation function 1 (AF1) that is essential for the receptor’s transactivation 
capacity (Figure 3). Exons 3 and 4 each encode for their respective zinc finger motifs that 
constitute the DNA-binding domain (DBD) of the receptor. Exons 5 to 9 contain the 
sequence for the ligand-binding domain (LBD) in which the activation function 2 (AF2) 
is embedded (Encío and Detera-Wadleigh 1991).
The	two	GR	isoforms,	GRα	and	GRβ,	arise	from	the	alternative	splicing	of	the	exon	9	
(Encío and Detera-Wadleigh 1991).	GRα	is	considered	the	“classical”	GR	of	777	aa.	Its	shorter	
counterpart	 GRβ	was	 originally	 thought	 to	 be	 unable	 to	 bind	 ligand,	 and	 considered	
merely	as	a	dominant	negative	inhibitor	of	GRα-dependent	transactivation	(De Castro et al. 
1996).	However,	more	recent	studies	have	shown	that	GRβ	might	be	able	to	interact	with	
GRα	partial	agonist/antagonist	RU-486	and	is	able	to	regulate	gene	expression	even	in	
the	absence	of	GRα	(Kino et al. 2009a).	The	ability	of	GRβ	to	antagonize	the	effects	of	GRα	
led	to	the	idea	that	GRβ	may	be	involved	in	the	tissue-specific	sensitivity	to	GCs,	and	
GRβ	expression	has	been	shown	to	be	increased	in	GC-resistant	asthmatics	and	patients	
with IBD (Hamid et al. 1999, Orii et al. 2002). 
18
In 2005, Lu et al. reported that at least 8 different translation initiation sites exist 
for	hGRα.	These	GRα	isoforms	were	termed	GRα-A,	-B,	-C1,	-C2,	-C3,	-D1,	-D2	and	
–D3 (Figure 3) (Lu et al. 2005). The generation of the different isoforms is caused either by 
ribosomal leaky scanning or ribosomal shunting, where the ribosome initiates translation 
of the mRNA from alternative translation initiation sites located in the exon 2 (Lu et al. 
2005). Thus, the generated proteins differ from their amino-terminal region but have 
similar	DNA-	and	ligand-binding	domains.	The	expression	levels	of	these	GRα	isoforms	
varied between different tissues, as did their transactivation capacity on synthetic GC 
response element (GRE) -driven promoter (Lu et al. 2005). In addition, every isoform had 
its own target-gene expression profile when cDNA microarray data were studied (Lu et al. 
2005). It has been hypothesized that similar N-terminal receptor isoforms would also exist 
for	GRβ,	which	would	 increase	 the	amount	of	different	N-terminal	GR	isoforms	 to	at	
least 16 (Chrousos and Kino 2005).	The	discovery	of	these	multiple	hGRα	and	putative	GRβ	
isoforms further increases the capacity of the GR to modulate its signal transduction.
Other GR isoforms identified until now include the GR-P (lacking aa encoded by 
exons 8 and 9) and GR-A (lacking aa from exons 5, 6 and 7) that have been detected at 
high levels in GC-resistant myeloma patients (Figure 3) (Krett et al. 1995, Moalli et al. 1993). 
GRγ,	 in	 contrast,	 is	 a	 receptor	 variant	 found	 for	 example	 in	 childhood	 lymphoblastic	
leukemia that has an insertion of an additional arginine in the intron between exons 3 
and 4 (Rivers et al. 1999, Beger et al. 2003). The insertion of the arginine between the two zinc 
fingers of the DBD decreases the transactivation potential of the receptor by 50% (Beger 
et al. 2003, Ray et al. 1996). 
In addition to the receptor isoforms, several polymorphisms have been found in the 
GR gene. Two of these, ER22/23EK and N363S, reside in the exon 2 and are reported to 
associate with relative GC resistance and sensitivity respectively (van Rossum and Lamberts 
2004). The third polymorphism called BclI lies in the intron between exons 2 and 3. The 
data on BclI polymorphism has been controversial; at present however, the majority of 
the studies promote the idea that BclI is also linked to increased GC sensitivity (van 
Rossum and Lamberts 2004). In a small group of IBD patients, the frequency of the BclI 
polymorphism has been shown to be increased in patients with CD (Decorti et al. 2006). The 
fourth	polymorphism,	GR-9β,	is	a	polymorphism	in	the	exon	9β	3’	nontranslated	region.	
In vitro data indicate that the nucleotide substitution in this polymorphism causes the 
hGRβ	mRNA	to	be	more	stable,	which	might	lead	to	a	relative	GR	resistance	(Derijk et al. 
2001). 
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1.2.2 Structure
Similar to other steroid receptors, the structure of hGR is modular, and its three different 
domains have distinct functions (Mangelsdorf et al. 1995). 
The N-terminal domain (NTD, aa 1-420) is the least conserved and varies even 
between different hGR isoforms (Figure 3) (Kumar and Thompson 2005). NTD contains the 
AF1 domain that is responsible for much of the receptor’s transcriptional activity. AF1 has 
been shown to be able to interact with the coregulatory proteins and general transcription 
machinery, and to significantly enhance the receptor’s transcriptional capacity (Kumar and 
Thompson 2005). NTD also contains the GRs major phosphorylation sites that can further 
modulate the receptor’s ability to affect target-gene transcription (Duma et al. 2006).
The median domain DBD (aa 421-526) is highly conserved and harbours the two zinc 
finger motifs that interact with the GREs on target genes (Duma et al. 2006). Beside the DBD 
lies the hinge region (HR) that allows the receptor to bend and change conformation (Tsai 
and O’Malley 1993). Upon ligand binding, the conformation of the receptor changes and 
uncovers the nuclear localization signal (NLS1) that is necessary for the recognition by 
the transport machinery of the cell (Hager et al. 2000).
The LBD (aa 527-777) is the site of hormone binding. The amino acids of this segment 
form a hydrophobic loop that closes when the ligand is bound, and the freshly shaped 
molecule presents new surface for coregulator binding. LBD contains the second nuclear 
localisation signal (NLS2) and activation function 2 (AF2) (Duma et al. 2006).  
GR is a subject of post-translational covalent modifications that can further affect 
the receptor’s activity (Figure 3). Phosphorylation of specific serine residues can either 
activate or repress the receptor’s functions, whereas ubiquitination regulates the GC 
signalling pathway via controlling the degradation rates of GR (Wallace and Cidlowski 
2001, Duma et al. 2006). Sumoylation of the receptor affects the GR in a promoter-context 
dependent fashion, either activating or repressing its function (Tian et al. 2002). Acetylation 
and methylation have also been shown to affect GR; however, their effect seems not to 
be direct but occurs through modulating the functions of core histones and coregulatory 
proteins (Duma et al. 2006).
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Figure 3 The structure of the GC receptor (Gr): A) The Gr gene consists of at least 9 alternative 
exon 1s (A-J) and 8 other exons. The polymorphisms of the Gr are presented at their 
respective positions in the gene. b) The mrNA transcript variants of the Gr gene. For Grα 
the presence of the different translation initiation sites for A-d3 isoforms is schematically 
presented. Arg, arginine. C) The full-length Grα, its main functional domains and the sites 
of post-translational covalent modifications: S, sumoylation; Ub, ubiquitination.
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1.3 Mechanism of action
1.3.1 Genomic actions
Both natural and synthetic GCs are lipophilic proteins that enter the cells via diffusion. 
The GR resides mainly in the cytoplasm as a part of a multiprotein complex, with heat 
shock protein (hsp) 90s, hsp70, immunophilins, Cyp-40 and p23. Upon ligand binding, 
GR dissociates from the protein complex, partly homodimerizes and translocates to 
nucleus (Duma et al. 2006). The translocation through nuclear pores is an active process 
mediated by the NLS1 and NLS2 (Chrousos and Kino 2005). Once inside the nucleus, the 
ligand-receptor dimer transactivates or represses the expression of the target genes by 
binding directly to the positive or negative GREs on promoter regions. The AF1 and 
AF2 domains mediate the interaction of GR with nuclear receptor coregulator and 
chromatin remodeling complexes that ultimately affect the RNA II polymerase activity 
and thereby the transcription velocity of the GC responsive genes. The ligand-activated 
GRα	monomers,	 in	contrast,	modulate	the	gene	transcription	by	interacting	with	other	
transcription	 factors	 [activating	 protein	 1	 (AP1),	 nuclear	 factor	 κB	 (NFκB),	 p53	 and	
others] and influencing their activity on their own target genes (Chrousos and Kino 2005). 
1.3.2 Nongenomic actions
In addition to these classical genomic actions of GCs that require the modulation of gene 
expression and take from minutes to hours to be operative, other so-called nongenomic 
effects of GR are being investigated. Characteristic of the nongenomic actions is that 
they occur rapidly within seconds to minutes, and do not require the classical pathway of 
ligand-binding, translocalization to nucleus and binding to DNA target sequences (Stellato 
2004). At present, the nongenomic effects of GR are divided into three categories: 1) 
nongenomic effects without receptor involvement, 2) nongenomic actions via classical 
intracellular receptors, 3) nongenomic actions via nonclassical receptors (Falkenstein et 
al. 2000). An example of the first category is that steroids have been shown capable of 
diffusing easily in the lipid membranes, thus possibly interacting with the ion channels and 
receptors within the membranes with no contact to their intracellular cognate receptors. 
The second category necessitates contact between ligand and receptor. However, treatment 
with transcription inhibitor does not abolish these effects, thus they are probably not 
mediated through traditional genomic ways but could for example activate different 
kinase pathways. The third category calls in the newly identified membrane-bound GR, 
the functions of which remain elusive as yet (Löwenberg et al. 2008). 
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2. Pharmacological glucocorticoid therapy
Pharmacological GC therapy was initiated with the first successful injection of cortisone 
acetate to patients with rheumatoid arthritis in 1948. Today, GCs are the most commonly 
prescribed anti-inflammatory preparations and exceed many other drugs in terms of the 
variety of applications and the number of patients treated (Schäcke et al. 2002). It is estimated 
that between 1% and 3% of the adult population worldwide use long-term GC therapy 
(Walsh et al. 1996, Van Staa et al. 2000). Statistics on drug consumption in Finland and other 
Nordic countries reveal that the use of steroids is still increasing and that more people are 
exposed to the effects of systemic GC therapy (Figure 4). 
Figure 4 The use of systemic GCs in Finland (black bars), Sweden (white bars), Norway (grey bars) 
and denmark (grey and black bars) between the years 1988-2008 expressed as defined 
daily doses per 1000 inhabitants per day (National Agency for Medicines, Apoteket Ab/
Statistiksenheten, Nasjonalt folkehelseinstitutt, The danish Medicines Agency). 
Steroid therapy is utilized in inflammatory, autoimmune, collagen, renal, gastrointestinal, 
respiratory, nervous, hematologic, dermatologic and ophthalmic diseases, transplantations, 
neoplastic disorders, medical emergencies and infections. In addition, GCs are used in 
replacement therapy for patients with primary or secondary adrenal failure as well as in 
suppression therapy in congenital adrenal hyperplasia. The large array of applications 
reflect the wide range of effects that GCs have from inhibiting cell-mediated immune 
function to altering metabolic conversion of non-steroidal hormones from inactive to 
active forms (Stewart 2008).
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Synthetic GCs are derivatives of the natural GC skeleton where the basic steroid 
nucleus or its side chains have been altered (Figure 2). These changes affect the 
pharmacokinetic properties of these compounds (absorption, metabolism, protein binding 
and tissue distribution) as well as their GC and mineralocorticoid potencies (Stewart 2008, 
Axelrod 2003). The characteristics of commonly used GC agents are presented in Table 1. 
Table 1 The properties of synthetic GCs using cortisol as a standard (adapted from rang et al. 
2007). 1 Human foetal lung cells, 2 budesonide data obtained from edsbäcker et al. 2004.
Compound relative affinity  
for GC receptor1
Approximate relative potency  
in clinical use
duration of action 
after oral dose
Anti-
inflammatory
Sodium 
retaining
Cortisol 1 1 1 short (8-12)
Prednisolone 2.2 4 0.8 short (8-12)
Methylprednisolone 11.9 5 minimal intermediate
Triamcinolone 1.9 5 none intermediate
dexamethasone 7.1 30 minimal long
betamethasone 5.4 30 negligible long
budesonide2 195 nd nd very short (2-4.5)
Aldosterone 0.38 none 500 -
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2.1 Side-effects    
GC therapy is associated with several side-effects (Figure 5) (Schäcke et al. 2002, Fardet et al. 
2007, McDonough et al. 2008, Rhodes et al. 2008). Of patients treated with conventional doses of 
GCs, as many as 80-90% report at least one side-effect during therapy (Curtis et al. 2006). 
The adverse events vary in terms of severity from cosmetic (Cushingoid appearance) to 
life-threatening (gastric haemorrhage) (Schäcke et al. 2002). However, especially in children 
and	adolescents,	the	less	serious,	“merely	cosmetic”	side-effects	can	be	a	cause	for	great	
anxiety, and the more severe events (osteoporosis, cataracts) go initially unrecognized 
(Huscher et al. 2009). Also, we have no information as to whether the appearance of the 
frequently	observed,	GC	 treatment-related	“mild”	side-effects	early	on	during	 therapy	
could be a sign of underlying GC sensitivity, and possibly predict either the treatment 
success and/or the appearance of more severe adverse events.
Eye:
Cataracts
Galucoma
Body disfiguration:
Moon face with red (plethoric cheeks)
buffalo hump
increased abdominal fat
Thinning of the extremities
Cardiovascular system:
Hypertension
dyslipidemia & Obesity
Thrombosis
Muscle and skeleton:
Muscle atrophy/myopathy
Osteoporosis
Avascular necrosis of the femoral head
Endocrine system, metabolism:
Cushing’s syndrome
diabetes
Adrenal atrophy
Growth retardation
Hypogonadism, delayed puberty
Immune system:
increased susceptibility to infection
reactivation of latent viruses
Skin:
Atrophy
Striae
Steroid acne
Poor wound healing
Purpura
Teleangiectacia
Petechia
easy bruising
Gastrointestinal:
Peptic ulcer
Pancreatitis
Gastrointestinal 
bleeding
Psyche:
euphoria
Sleep disturbance
depression
emotional lability
Psychotic symptoms
Figure 5 GC-related side-effects (Schäcke et al. 2002, Fardet et al. 2007, Mcdonough et al. 2008, 
rhodes et al. 2008).
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2.1.1 dose and duration
The frequency of the reported adverse events increases with dosage, or when the 
treatment period extends while the dose remains constant (Huscher et al. 2009, Curtis et 
al. 2006). The early days of GC treatment saw a myriad of GC-related adverse events 
linked to high dose steroid therapy. Since then, the principle of primum non nocere in 
GC therapy has translated into the attempt to treat patients with as low effective dose as 
possible. Historically, doses less than 7.5-10 mg/day of prednisone equivalents have been 
considered low due to decreased rates of adverse events (Da Silva et al. 2005). There has been 
some controversy regarding the true incidence of the GC-related side-effects, especially 
in this low dose group, due to limitations in the study design as well as the confounding 
effects of the underlying disease (Da Silva et al. 2005). However, a number of studies do 
support the concept that even doses less than 10 mg/day of prednisone equivalents are 
associated with increased frequency of fractures, cataracts, skin bruising, acne, weight 
gain and cushingoid phenotype and increased risk of infections and fractures, especially 
if the treatment is long (Curtis et al. 2006, Wolfe et al. 2006, Vestergaard et al. 2008, Huscher et al. 
2009). 
2.1.2 Side-effects in paediatric patients 
Children may be even more sensitive to the GC-related side-effects than adults. In a 
Japanese report, paediatric patients with UC had higher incidence of osteoporosis, 
glaucoma and cataracts after steroid therapy than adults, even when adjusted to weight-
based dosing (Uchida et al. 2005). In addition, in children major GC-related side-effects 
occurred at a significantly lower preoperative dosing of steroids (Uchida et al. 2005). 
A special concern in the paediatric population receiving steroid therapy is growth. In 
children with CD, 19% of the patients receiving low-dose prednisone (0.1 – 0.4 mg/kg/
day) treatment were found to have growth suppression, even though their growth velocity 
before GC therapy was normal. Also, fracture risk in paediatric patients requiring 4 or 
more courses of oral GCs or using 30 mg prednisolone or more each day has been shown 
to be increased (Van Staa 2003).
2.1.3 Mechanisms of the side-effects
Today, the commonly agreed view is that the desired anti-inflammatory effect of GC 
therapy is mediated through transrepression, and that the majority of the unwanted events 
come via transactivation or non-genomic repression (Schäcke et al. 2002, Buttgereit et al. 2005). 
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However, at present the exact molecular mechanisms for most of the GC effects remain 
unclear (Table 2). 
Table 2 Common GC therapy induced side-effects and the possible mechanisms  behind them 
(adapted from Schäcke et al. 2002). x, mechanism mediating  the Gr effect; s, suspected 
mechanism of the Gr effect.
Mechanism
DNA-dependent DNA-independent
Side-effect Molecule Transactivation Transrepression Repression
Osteoporosis Osteoblast/
osteocyte apoptosis
x
Osteocalcin x
Type i collagen s
Skin atrophy Type i collagen s
Type iii collagen s s
decreased wound 
healing
down-regulation of 
proinflammatory genes
x
Muscle atrophy/
myopathy
Components of the 
ubiquitin-proteasome 
pathway
s
Suppression of HPA 
axis
CrH x
POMC/ACTH x
Psyche 5-HT
1A
receptor x
Glaucoma Fibronectin s
Type iv collagen s
Type i collagen s
Hypertension αenaC x
sgk x
diabetes mellitus 
induction
AAT
PePCK
x
x
3. Glucocorticoids in paediatric inflammatory bowel disease 
3.1 Paediatric inflammatory bowel disease
Inflammatory bowel disease (IBD) comprising ulcerative colitis (UC) and Crohn’s disease 
(CD) is an immune-mediated chronic disorder that results in relapsing inflammation of 
the gastrointestinal tract. Although the exact pathogenetic mechanism behind the onset of 
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IBD remains unknown, the generally accepted hypothesis is that it occurs in a genetically 
susceptible host as a result of an inappropriate and exaggerated mucosal immune response 
to ubiquitous environmental antigens including commensal microflora. 
Approximately 25% of IBD cases manifest during childhood, the mean age at 
diagnosis in paediatric patients being around 13-14 years (Griffths 2004, Turunen et al. 2006). 
The incidence of paediatric IBD is increasing; in Finland between the years 1987 and 
2003 the incidence almost doubled to 7.0/100 000 (Turunen et al. 2006). The cause for this 
rise in the incidence rates in the Western world remains obscure; however, the role of 
some environmental and other risk factors as potential contributors to the onset of the 
disease has been extensively discussed (Table 3).
Table 3 The role of environmental and other risk factors that have been associated  with the 
incidence of ibd (Saeed and Kugathasan 2008). 
Risk factor   Ulcerative colitis   Crohn’s disease
Smoking Protective Predisposing
Specific infectious agents Unclear Unclear
intestinal commensal flora Predisposing Predisposing
Appendectomy Protective Predisposing
breast feeding Unclear Unclear
dietary factors Unclear Unclear
drugs
    Oral contraceptives
    NSAids
nd
Predisposing
Predisposing
Predisposing
Sedentary lifestyle Predisposing Predisposing
3.1.1 Pathogenesis
As reported above, the aetiological trigger behind the onset of paediatric IBD is still 
unknown. However, the heterogeneity of the disease phenotypes does imply that IBD is 
a polygenic disorder in which the disease susceptibility loci and other disease-modifying 
genes together with environmental factors customize the specific disease subtype of an 
individual patient.
A number of genes have been associated with the development and/or severity of 
IBD. In Crohn’s disease, one of the most studied candidates is the NOD2/CARD15 
gene located in the IBD1 locus on chromosome 16 (McGreal and Cho 2008). NOD proteins 
NOD1 and NOD2 are intracellular pattern recognition receptors that serve the innate 
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immune system as bacterial sensing molecules (McGreal and Cho 2008). Carriage of the 
NOD2/CARD15 mutations increases the susceptibility of developing CD, and in children 
has been associated with ileal disease location and increased risk of small bowel surgery 
(McGreal and Cho 2008). 20 to 65% of the children with ileal Crohn’s disease have been 
estimated to carry at least one NOD2/CARD15 mutation (McGreal and Cho 2008). Another 
actively investigated gene is the interleukin 23 receptor (IL23R) gene on chromosome 1. 
An uncommon coding variant of the IL23R gene has been shown to be protective against 
both UC and CD; however, the exact role of the IL-23 pathway in the inflammatory 
pathogenesis is still unclear (McGreal and Cho 2008). Other genes linked to IBD are for 
example the SLC22A4/A5 variants, DLG5 gene variants, polymorphisms in the HLA 
type,	multi-drug	 resistance	 (MDR1)	 gene	 variants	 and	 polymorphisms	 in	 the	NFκB1	
promoter (McGreal and Cho 2008).
The gastrointestinal tract harbours the most numerous collections of immune cells in 
the body. Its antigenic load of food, commensal flora and microbial pathogens is massive, 
and since it is the body’s largest interface with the external milieu, the intestinal mucosa 
has to orchestrate the pro- and anti-inflammatory responses in order to protect the 
organism from harmful bacteria and at the same time regulate itself to avoid uncontrolled 
immunological activation. By nature, these functions are complex and interrelated and it 
is somewhere along this pathway that IBD develops.
At least three different immunity-related mechanisms have been proposed as being 
involved in the development of IBD. Epithelial barrier – the continuous single layer of 
epithelial cells lining the gastrointestinal tract sealed by tight junctions – has been shown 
to be abnormally permeable in patients with CD and their first degree relatives (Faubion 
and Fiocchi 2008). This might lead to an excessive antigen stimulation of the submucosal 
immune cells and eventually to mucosal inflammation. In addition, multiple lines of 
evidence suggest that the innate immune system is dysfunctioning in IBD patients. One 
of the most discussed theories is the existence of the above-mentioned NOD2/CARD15 
mutations that might lead to defective responsiveness to enteral bacteria, possibly 
promoting chronic inflammation (Faubion and Fiocchi 2008). Also adaptive immunity 
plays a role in the development of IBD, supported merely by the fact that established 
and emerging IBD therapy is directed against Th1-type cytokines and effector T cells 
(Ardizzone et al. 2005).
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3.1.2 Clinical presentation
Common clinical features in children with IBD include abdominal pain, weight loss, 
rectal bleeding and diarrhoea. However, the symptom patterns differ between UC, CD 
and IC (Table 4). Importantly, the presence of arthritis, fever, non-specific rash, weight 
loss or perirectal abscess can be the only findings of paediatric IBD (Blank and Keljo 2008).
 
Table 4 Symptom frequency (%) in newly diagnosed patients with inflammatory bowel disease 
(adapted from Sawczenko and Sandhu 2003).* data obtained from langholtz et al.
Symptom
Crohn’s disease  
(n=379)
Ulcerative colitis 
(n=172)
Indeterminate colitis 
(n=72)
Abdominal pain 72 72 75
diarrhea 56 74 78
rectal bleeding 22 84 68
weight loss 58 31 35
Fatigue 27 12 14
Anorexia 25 6 13
Fever* 48* 34* nd
Arthritis 7.5 6 4
Nausea / vomiting 6 0.5 1
Constipation / Soiling 1
Anal fistula 4.5
Growth failure / delayed puberty 4 1
Anal abscess, ulcer 2
erythema nodosum, rash 1.5 0.5
liver disease 0.8 3 3
Toxic megacolon 0.5
3.1.3 Clinical course
At present, there is no cure for IBD and the long term health outcome of the affected 
child is dependent on the disease activity, response to treatment, the possible side-effects 
brought about by the used therapeutic modality and the patients and their families ability 
to develop adaptation and coping strategies. 
Paediatric IBD differs from adult-onset disease in that the disease is often more 
extensive, presenting as pancolitis in UC and colitis or ileocolitis in CD (Heyman and Gupta 
2008, Vernier-Massouille et al. 2008). In paediatric CD, isolated ileal disease is rare (~10%) 
(Vernier-Massouille et al. 2008). Risk factors for surgery in CD include stricturing disease 
phenotype at diagnosis and GC treatment; the overall risk being around 30-40% at 5-8 
30
years from diagnosis (Vernier-Massouille 2008, Turunen et al. 2009). In paediatric UC, the risk 
of surgery is significantly higher than in adults. In Finland, 24% of the young adults 
diagnosed with pediatric onset UC a median of 8 years earlier have undergone surgery 
(Turunen et al. 2009). Other studies report similar figures (Gower-Rousseau et al. 2009). 
The onset of a lifelong debilitating illness in adolescence, during a critical 
developmental period, is a major psychosocial stress factor. Therefore, paediatric patients 
with IBD are at risk of social isolation, depression and anxiety (Karwowski et al. 2009). 
Their parents report that the patients have more emotional and social problems and lower 
competence than their population-based peers (Väistö et al. 2010). Young adults diagnosed 
with IBD a median of 8 years previously report a decreased quality of life (Turunen et al. 2009). 
Strategies to improve the well-being of the patients include psychosocial interventions 
and psychotherapy, social support, education and self-management (Karwowski et al. 2009).
3.1.4 Therapeutic options 
Goals for the therapy in paediatric IBD are the induction and maintenance of remission, 
prevention of cancer of the affected bowel, facilitation of normal growth and development 
and improvement of the quality of life (Carvalho et al. 2007). The choice of treatment depends 
on disease subtype, localization and associating presenting features such as weight loss 
and short stature (Sandhu et al. 2010). In moderate to severe IBD, the current therapeutic 
strategy may involve 5-aminosalicylate (5-ASA) preparations, systemic and topical GCs, 
immunomodulators (e.g. 6-mercaptopurine, azathioprine, methotrexate and cyclosporine), 
nutritional interventions, biologic therapy and surgery (Markowitz et al. 2008). 
5-ASA preparations sulfasalazine and mesalamine are a widely used first-line 
treatment of paediatric IBD (Sutherland et al. 2006a, Sutherland et al. 2006b, Moyer 2008). The 
precise mechanism of action of these drugs is as yet unclear; however, one of the most 
important effects is probably the inhibition of the cyclo-oxygenase that impedes the 
production of pro-inflammatory prostaglandins and leukotrienes (Moyer 2008). In UC, 5-
ASA preparations are used in the induction and maintenance of remission (Sandhu et al. 
2010). In CD, aminosalicylates are employed in the induction of remission; however, their 
role in the maintenance of remission is still unclear (Wilson et al. 2010).
Nutritional management of children with IBD is essential and the nutritional status 
of the patient should be addressed at each control visit (El Matary and Zachos 2008). In 
addition, exclusive enteral feeding with polymeric or elemental formulas may be used in 
the induction of remission in CD patients, especially if the patients present with growth 
failure (Sandhu et al. 2010). 
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Immunomodulators, mainly azathioprine or 6-mercaptopurine, are employed in 
patients with moderate to severe colitis that are refractory or unresponsive to induction 
therapy with salicylates and steroids, or fail to wean off GC treatment (Prefontaine et al. 2009a, 
Prefontaine et al. 2009b, Timmer et al. 2007, Sandhu et al. 2010). These agents are immunosuppressive 
and lymphocytotoxic and the measurement of the thiopurine S-methyltransferase (TPMT) 
alleles is encouraged before their introduction to avoid serious side effects (Cuffari 2008). 
Methotrexate is another option that can be considered for treatment-resistant patients 
(Alfadhli et al. 2004, Patel et al. 2009, Sandhu et al. 2010). 
Infliximab is the most studied preparation of the new biologic pharmaceuticals and 
has been established in the treatment algorithm of refractory CD (Akobeng and Zachos 2004, 
Behm and Bickston 2008, Rutgeerts et al. 2009). Infliximab is a chimeric monoclonal antibody 
to	TNF-α,	and	in	adults	it	has	been	shown	to	induce	and	maintain	remission	(Wilson et al. 
2010). However, studies in paediatric patients are still few, and with the risk of rare but 
serious adverse events (sepsis, increased risk for hepatosplenic T-cell lymphoma), at the 
moment infliximab is reserved for patients with severe disease that are unresponsive to 
conventional therapy and for whom surgery is not recommended (Wilson et al. 2010).  
3.2 Glucocorticoid therapy in paediatric IBD
GCs have been used in the treatment of active IBD since the 1950s (Truelove and Witts 
1955). Today, they are utilized in the induction of remission in moderate to severe IBD in 
both paediatric and adult populations (Rufo and Bousvaros 2006, Domènech 2006). Strikingly 
few studies have focused on the optimal dose or dosage tapering for GC treatment 
in adult patients (Baron et al. 1962, Rutgeerts 2001). In children, the treatment strategy has 
been extrapolated from the experience in adults. At present, the recommended dose 
for traditional GCs (prednisone, prednisolone) in paediatric patients is 1-2 mg/kg/day 
prednisone equivalents (max 60 mg/day) for ~2 weeks followed by a tapering period 
of 4-8 weeks (Rufo and Bousvaros 2006). Maintenance therapy or alternate-day therapy 
with steroids are generally not recommended (Rufo and Bousvaros 2006, Escher et al. 2003). A 
newer synthetic GC, budesonide, that has high affinity for the GR, enhanced first-pass 
metabolism and low systemic bioavailability has been studied in the treatment of CD 
(McKeage and Goa 2002, Rufo and Bousvaros 2006). A recent Cochrane review, however, stated 
that budesonide seems to be less effective than conventional steroids in the treatment 
of CD, specifically if the patients have more extensive colonic involvement or severe 
disease (Seow et al. 2008).
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3.2.1 response to glucocorticoid therapy
Studies investigating the response rates to oral GCs in paediatric IBD differ in their primary 
outcome measures and in how the response, lack of response and steroid dependency are 
defined. In addition, therapeutic response in a heterogenous disease such as IBD is influenced 
by the duration of the disease, disease behaviour and disease severity. This makes the 
comparison between different studies challenging. Two recent studies on newly diagnosed 
paediatric (<16 years of age) UC (n=97) and CD (n=109) patients found that after 3 months 
of treatment with conventional steroids (oral prednisone or i.v. methylprednisolone 1-2 
mg/kg/day) around 85% of the patients showed inactive/mild disease or complete/partial 
response respectively (Hyams et al. 2006, Markowitz et al. 2006). After 1 year, 50-60% of the patients 
were defined as GC responsive, 30-40% as GC dependent and 5-8% had required surgery 
(Hyams et al. 2006, Markowitz et al. 2006). In these studies the outcome measure was clinical: 
physician global assessment (PGA) and/or the continuation or successful withdrawal of 
GC therapy. However, an older study by Beattie et al. showed that clinical response does 
not often correlate with endoscopic or histologic findings. After 8 weeks of GC therapy, 
85% of the paediatric patients demonstrated complete remission in clinical disease activity, 
but only 40% showed complete endoscopic and 15% full histological remission (Beattie 
et al. 1996). In adult studies, the clinical response rates to GC therapy have been similar to 
children, although the number of steroid-resistant patients has been higher, possibly due to 
longer disease duration or more severe disease (Table 5).
Table 5 Steroid resistance in adult patients with ibd (modified from Creed et al. 2007).
Trial
No. of 
Pat.
Disease/
treatment
Severity Remission
Partial 
response 
Resistance 
Truelove and witts 
1955
109
UC / oral 
cortisone
Mild, 
moderate 
& severe 
41.3% 27.5% 31.2%
Truelove et al. 1978 87 UC / iv steroids Severe 60% 15% 25%
Chakravarty 1993 89 UC / iv steroids Severe 72% - 28%
Munkholm et al. 
1994
109 Cd / oral steroids
Moderate & 
severe
48% 32% 20%
Travis et al. 1996 49 UC / iv steroids Severe 42% 31% 27%
lindgren et al. 1998 97 UC / iv steroids Severe 40% 26% 34%
Faubion et al. 2001 63
UC / oral or iv 
steroid
Moderate & 
severe
54% 30% 16%
74 Cd / oral steroids
Moderate & 
severe
58% 26% 16%
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3.3 Glucocorticoid sensitivity/resistance in IBD
Only 40-70% of the patients with active IBD enter clinical remission during GC treatment 
(Table 5), and around 20% show resistance to the therapeutic effects of the administered 
steroids. Unfortunately, the population that fails to respond to GC therapy might still 
suffer from the adverse effects associated with steroid treatment. Thus, GC sensitivity 
differs between individuals, and between cells and tissues of a single subject. 
3.3.1 ligand availability
The first possible step that could influence the patient’s response to administered GCs is 
the absorption and/or metabolism of these agents. However, the absorption of prednisolone 
in paediatric IBD patients with both active and quiescent disease seems unaffected (Olivesi 
1985, Faure et al. 1998, Schwab et al. 2001). Once in the circulation, GCs bind to CBG. Only 
the	unbound,	“free”	GCs	are	capable	of	diffusing	through	the	cell	membranes	to	exert	
their actions, and thus the relative concentration of transcortin is another determinant of 
GC activity (Breuner and Orchinik 2002). Reduced levels of CBG have been found in diverse 
inflammatory conditions, as well as during stress and hypercortisolemia (Marques et al. 
2009); however no alterations in the CBG levels of IBD patients have been reported.
The	metabolism	of	the	administered	GCs	by	11β-HSD	enzymes	could	alter	the	ligand	
availability	in	IBD	patients.	However,	studies	on	11β-HSD1	and	11β-HSD2	expression	
in IBD have shown that the former enzyme is upregulated and latter downregulated in 
the inflamed tissues (Žbánková	et	al.	2007,	Stegk	2009). Thus, the conversion of the GCs is 
predominantly from inactive to active form. Therefore, if the steroids are administered as 
an active form, as in our study, the variable metabolism of the GCs by the dehydrogenases 
should not alter the ligand availability. 
3.3.2 Access to the target cells
GCs enter their target cells mostly via passive diffusion. There is, however, an active 
mechanism, drug-efflux pump P-glycoprotein 170 that transfers GCs and other agents out 
of lymphocytes and intestinal epithelial cells. The expression of the multi-drug resistance 
gene (MDR1) that codes for the pump protein was previously shown to be elevated in 
IBD patients requiring bowel resection for failed medical therapy (Farrell et al. 2000). More 
recently, however, the contribution of the MDR1 to GC sensitivity in IBD patients has 
been questioned (Annese et al. 2006). 
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3.3.3 Glucocorticoid receptor in ibd
No IBD patients with primary GC resistance caused by mutations in the GR gene and 
leading to hypertensive, hyperandrogenic disorder characterized by high serum cortisol 
levels have been described in the literature. However, since the late 1990s, more subtle 
alterations in GR number and structure that could affect the therapeutic response to GC 
therapy have been reported (see below). 
3.3.3.1 Altered numbers of glucocorticoid receptors
The number of GRs in the peripheral blood mononuclear cells (PBMC) and colonic 
mucosal cells of IBD patients has been evaluated by various researchers (Table 6). The 
results have been conflicting. This probably reflects the different study designs applied in 
these studies, as well as the cells’ dynamic potential to up- and downregulate the expression 
of the GR and its cofactors in different situations. Rogler et al. (1999) suggested that the 
GR numbers are decreased in the colonic mucosa of all IBD patients, lower in the PBMC 
of the steroid-treated patients, and similar to controls in the PBMC of the IBD patients 
not on steroids. Flood et al. (2001), in contrast, reported GR mRNA levels to be higher in 
IBD patients than in the controls. A third study stated that no difference in the expression 
of GR mRNA between IBD patients and the controls could be seen (Raddatz et al. 2004). In 
other diseases, altered GR numbers and affinity have been associated with response to GC 
treatment; in IBD however, more studies would be needed to answer these questions.
3.3.3.2 Altered affinity to the ligand
Another mechanism for varying responses to administered exogenous steroids could be 
the altered affinity of the steroid receptor to its ligand. In IBD, Shimada et al. (1997) found 
that in the PBMC of steroid-resistant patients the affinity of the GR to GCs was decreased 
(Table 6). Similarly, in another study on patients with mild to moderately active IBD, 
both steroid-treated and steroid-free IBD patients had a higher dissociation constant of 
GR in their PBMC than normal controls (Schottelius et al. 2000). Even though these studies 
are relatively small, they do promote the hypothesis that systemic inflammation present 
in active IBD could alter the affinity of the GR to its ligand, a phenomenon seen for 
example in severe asthma (Irusen et al. 2002).
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Table 6 Studies evaluating Gr number and affinity in peripheral blood mononuclear  
cells (PbMC) and colonic mucosa and their relationship to GC therapy  
response in adult ibd patients. dex, dexamethasone.
Pat. Dis. Objective Method Results
Shimada  
et al. 1997
11 UC To study the number of 
Gr and their affinity to 
ligand in PbMC
whole cell 
[3H]dexamethasone  
binding assay
Steroid non-responders (n=6) 
had higher number of Gr 
binding sites than responders 
(n=5) or controls and lower 
affinity of Gr to ligand than 
responders.
rogler et  
al. 1999
31
18
Cd
UC
To study Gr receptor 
numbers in PbMC and 
colonic mucosa
Cytosolic
[3H]dexamethasone 
radioassay
Mucosal Gr levels were 
decreased in ibd patients 
when compared with 
controls. in steroid-treated 
ibd patients Gr numbers 
were lower in PbMC.
Schottelius 
et al. 2000
22
17
UC
Cd
To investigate the 
expression of Gr 
and their apparent 
dissociation constant in 
PbMC of ibd patients
whole cell 
[3H]dexamethasone  
binding assay
in ibd patients the K
d
 was 
constantly higher than in the 
healthy controls. ibd patients 
not on steroid therapy had 
higher Gr levels than steroid-
treated ibd patients or 
controls.
Flood et al. 
2001
21 UC To study Gr mrNA 
levels in peripheral 
leukocytes and the 
effect of low-dose dex 
treatment on them
Quantitation of  
Gr mrNA in solution 
hybridization assay
Gr mrNA levels were higher 
in ibd patients than in the 
controls. The mrNA levels 
were the same between 
steroid responders (11) and 
non-responders (10).
raddatz et  
al. 2004
33
21
UC
Cd
To study Gr mrNA 
expression in PbMC 
and colonic mucosa 
of  ibd patients and 
whether they correlate 
with disease activity 
or can predict GC 
treatment response
Quantitation of 
Gr mrNA by 
rT-PCr, immuno-
histochemistry
Systemic and local Gr mrNA 
expression was similar to 
controls; however in the 
mucosa of UC patients with 
impaired GC response the 
levels were down-regulated. 
Gr immunoreactivity was 
found in immune and 
epithelial cells. 
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3.3.3.3 Glucocorticoid receptor isoforms α and β
The	expression	of	GR	isoforms	α	and	β	has	also	been	studied	in	IBD	patients	(Table	7).	
A	number	of	 reports	 support	 the	 concept	 that	 the	GRβ	 receptor	 isoform	 is	 a	 possible	
determinant	of	GC	sensitivity	 in	 IBD	patients.	GRβ	expression	has	been	shown	 to	be	
increased in PBMCs as well as colonic mucosal cells of GC resistant IBD patients (Honda 
et al. 2000, Orii et al. 2002, Zhang et al. 2005, Towers et al. 2005, Fujishima et al. 2009). However, the 
largest study on the subject, of 86 IBD patients, arrived at opposing results (Hausmann et al. 
2007). Although the differences in the clinical setting could explain the divergent results, 
the	precise	role	of	the	GRβ	isoform	in	IBD	as	well	as	in	other	diseases	is	yet	to	be	fully	
clarified (Kino et al. 2009b).
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Table 7 Studies assessing the association between GC therapy response  
and the number of Grα and Grβ in adult ibd patients. 
Pat. Dis. Objective Method Results
Honda et  
al. 2000
23 UC To study whether rT-
PCr analysis of hGrβ 
mrNA in PbMC of UC 
patients can predict the 
response to GC therapy.
Grα and Grβ  
analysis by mrNA  
rT-PCr,  
western-blot
Grβ was positive in 83.3% 
of the GC non-responders 
(n=12) and in 9.1% of the 
GC-responsive patients 
(n=11).
Orii et al.  
2002
34
13
UC
Cd
To quantify the levels 
and serial changes of 
PbMC Gr mrNA in ibd 
patients.
real time  
fluorescence 
monitored PCr
Grβ mrNA expression was 
increased in active UC. Grβ 
mrNA expression was also 
higher in GC-resistant than 
GC-sensitive UC.
Hori et al.  
2002
17 Cd To quantify the levels of 
Gr mrNA in PbMC.
rT-PCr Grα and Grβ mrNA levels 
were lower in patients with 
Cd than in the controls. The 
longer the disease duration, 
the lesser the amount of 
Grα mrNA in PbMCs of the 
patients.
Zhang et 
al.  
2005
25 UC To study the expression 
of Grα and Grβ in 
colonic mucosal cells 
and their correlation with 
response to GC therapy 
and inflammation.
immuno- 
histochemistry
The expression of Grα was 
positively associated with 
response to GC treatment, 
whereas Grβ associated 
negatively with the response 
to GCs.
Towers et 
al. 2005
42 Cd To assess the expression 
of Grα and Grβ in 
PbMCs of Cd patients 
and to study their 
relationship to the 
response to GC therapy.
rT-PCr using 
real-time PCr 
techniques, il-
18 levels were 
measured with 
eliSA.
Grβ mrNA expression was 
significantly higher in GC 
non-responders with active 
Cd. in these patients, Grβ 
mrNA correlated directly 
with il-18 levels measured 
from the serum.
Hausmann 
et al. 2007
86 ibd To study whether Grβ 
expression in PbMCs of 
ibd patients could serve 
as a predictor of GC 
response
rT-PCr Grβ expression was similar 
between GC-treated and 
non-GC-treated patients and 
between GC-responders and 
non-responders.
Fujishima  
et al. 2009
38 UC To study the relationship 
between the frequency 
and type of infiltrating 
cells expressing Grα, 
Grβ and Foxp3 in 
biopsied colonic 
mucosa and the GC 
responsiveness of UC 
patients.
immuno- 
histochemistry,  
rT-PCr.
GC non-responders  had 
higher Grβ+cell count than 
GC-responders. The Foxp3+ 
cell count was significantly 
higher in GC-responders. 
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3.3.3.4 Glucocorticoid receptor polymorphisms
The only GR characteristic investigated in the paediatric population in IBD patients 
are the single-nucleotide polymorphisms (SNPs) located within the GR gene (Table 8). 
The studies were conducted by an Italian group that reported the BclI polymorphism 
to be significantly more frequent in GC-responsive patients than in GC-dependent or 
unresponsive patients (De Iudicibus et al. 2007). This is one of the most promising markers 
of GC-sensitivity discovered so far, even though the confirmation of these findings in 
larger studies as well as their association with other markers reflecting steroid sensitivity 
is still lacking.
Table 8 Studies on Gr polymorphisms in paediatric ibd patients.
Pat. Dis. Objective Method Results
decorti et al. 
2006
23
34
UC
Cd
To study Gr 
polymorphisms in ibd.
Genomic dNA 
extraction 
from PbMCs 
and digestion 
with specific 
restriction 
enzymes.
The frequency of the bcli 
polymorphism of the Gr 
gene, associated with 
increased sensitivity to GCs, 
was found to be higher in 
patients with Cd.
de iudicibus 
et al. 2007 
55
64
UC
Cd
To study  the impact of 
genetic variations in hGr 
and Mdr1 genes on the 
efficacy and individual 
response to GCs in ibd
PCr-rFlP A significantly higher 
frequency of bcli  genotype 
was observed in the GC-
responsive patients.
4. Methods to assess glucocorticoid sensitivity
Two separate patient groups have to be considered when discussing methods to assess 
individual GC sensitivity. The first is the extremely small group of patients suffering 
from generalized GC resistance or sensitivity, conditions often caused by mutations in 
the GR gene (Russcher et al. 2006, Charmandari et al. 2008, Longui et al. 2009). These patients have 
alterations in the standard tests designed to study the HPA axis function and the diagnosis 
can be further confirmed by analyzing the GR gene (Charmandari et al. 2008). However, a 
problem is posed by the vastly larger population of otherwise healthy individuals who 
have more subtle alterations in their sensitivity to GCs which might manifest only as a 
poorer response to exogenous GC therapy (Chriguer et al. 2005). An ideal test to characterize 
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the alterations in the individual GC sensitivity in this large group would be cheap, simple, 
sensitive and relatively quick to perform. A number of mechanisms have been studied; 
however, at present we do not have any method in clinical use with which to predict in 
advance the patient’s response to GCs.  
4.1 Methods to assess glucocorticoid sensitivity in vivo
The dexamethasone suppression test (DST) is commonly used to study hypercortisol 
states in the clinical setting. In addition, it has been employed in studies assessing GC 
sensitivity (Flood et al. 2001, McMahon et al. 2009). Recently, a very low-dose (20 µg/m2 body 
surface area) dexamethasone suppression test was suggested as an index for GC sensitivity 
(Faria et al. 2008). However, even though the authors were able to show a spectrum of 
individual responses in different age groups, the findings were not correlated to any other 
parameters reflecting steroid sensitivity. In addition, no cut-off value was set for impaired 
GC sensitivity in this or other studies. DST measures the sensitivity of the pituitary GR 
to GCs. Inflammation, critical illness and mental disorders have been shown to alter the 
HPA axis responses (Bornstein 2008, Mawdsley and Rampton 2005). As GC sensitivity varies 
between different tissues even in healthy individuals, it is unclear whether the results of 
the DST correlate with the GC sensitivity of the target tissues.
Another test often employed in clinical practice is the adrenocorticotrophic hormone 
(ACTH) stimulation test (Kannisto et al. 2000, Dickstein and Saiegh 2008). It assesses the cortisol 
release from the adrenal cortex in response to exogenously administered ACTH (Dickstein 
and Saiegh 2008). At the end of systemic GC treatment, the ACTH test is routinely performed 
to assess the degree of suppression of the cortisol production which is considered to reflect 
the hypothalamic-pituitary GC sensitivity of the patient. In the previously described 
studies evaluating the GC response in IBD patients, only one study used the ACTH test 
as a variable (Flood et al. 2001). It arrived at conflicting results: after GC treatment, the non-
responders to GC therapy had the highest degree of cortisol suppression (Flood et al. 2001). 
Assays based on skin blanching are another method for evaluating the steroid 
sensitivity in vivo. In these assays, topical GCs are applied on the skin for varying time 
periods and the vasoconstriction caused by the steroid is calculated from the intensity 
of the blanching (Noon et al. 1996). Previous studies showed an association between GC 
sensitivity and skin blanching; however, more recent reports have contradicted these 
findings (Brown et al. 1991, Noon et al. 1996, Wilson et al. 2003). In IBD the skin blanching tests 
have not been used.   
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4.2 Methods to assess glucocorticoid sensitivity in vitro
The progress in the field of molecular and cell biology during the past 20 years has 
produced a large array of applications that can be used in studying GC sensitivity. With 
these technologies, the structure, expression and ligand binding and affinity of the GR 
has been studied in IBD patients (Tables 6, 7 and 8). In addition, more indirect methods to 
assess the GR effect such as the study of dexamethasone inhibition of phytohaemagglutin- 
or lipopolysaccaride-induced peripheral lymphocytes and studying other genes, their 
polymorphisms and cellular markers associated with the GC response have also been 
employed in IBD patients (Table 9).
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Table 9 Methods employed to study GC response in ibd patients. 
Pat. Dis. Objective Method Results
Hearing et 
al. 
1999
18 UC To study the hypothesis 
that GC-resistant UC 
patients have GC-
resistant T lymphocytes.
Phytohaemag-
glutin stimulated 
peripheral blood T 
lymphocytes treated 
with dexametha-
sone. 
Treatment failures and 
incomplete responders had 
an i
max
 of less than 60%, all 
complete responders had an 
i
max
 of more than 60%. 
Franchimont 
et al. 1999
19 Cd To compare the 
corticosensitivity of Cd 
patients to that of healthy 
subjects.
dexamethasone 
inhibition of lPS-
induced cytokine 
secretion by whole 
blood cell cultures.
Cd patients had a markedly 
decreased dexamethasone-
mediated inhibition of TNF-
α secretion.
Jinno et al. 
2006
30
15
UC
Cd
To study the lymphocytes 
in the colonic mucosa.
immunohistochem-
istry, flow cytometry.
High labelling of Cd19+ Ki-
67 lymphocytes was specific 
for active UC that was 
resistant to GC therapy.
Cucchiara 
et al. 2007
186
200
UC
Cd
To study the 
polymorphisms in the 
TNF-α and Mdr-1 genes 
that could affect the 
patients’ predisposition 
to ibd and response to 
therapy.
PCr-rFlP, dHPlC The TNF-α promoter 
polymorphism  
-308A carries a significant 
reduction in response to 
steroid therapy.
Nakahara 
et al. 2008
94
94
UC
Cd
To study the relationship 
between steroid 
responsiveness 
and SlC22A4/A5 
polymorphism located 
within ibd 5 locus.
Genotyping and 
haplotype analysis
The G allele on -368T>G in 
SlC22A5 was associated 
with steroid resistance in 
Cd patients.  Haplotype 
analysis between -446C>T 
and -368T>G in the 
SlC22A5 promoter region 
indicated CG allele as the 
risk haplotype for steroid 
resistance in Cd patients.
rintamäki 
et al. 2010
16
2
1
UC
Cd
iC
To study whether the 
sera from ibd patients 
treated with GCs causes 
immunological activation 
in PbMCs from healthy 
donors. 
eliSA, rT-PCr After the onset of GC 
treatment, the expression 
of  FOXP3 and GiTr 
decreased by 33% and 24% 
respectively. in addition, the 
levels of iFNγ in cell culture 
supernatant decreased.
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4.3 Circulating glucocorticoid bioactivity
The method of assessing GC treatment and sensitivity in this study was first published in 
2002 (Raivio et al. 2002). It is a COS-1 cell based bioassay in which the cells are transiently 
transfected with GR, coactivator androgen receptor interacting protein 3 (ARIP-3) and 
luciferase and galactosidase reporter genes. 10µl serum samples are added to the culture 
medium and after an overnight incubation, the cells are lysed and the activities of the 
reporter genes are measured. The resulting GC bioactivity (GBA) can be read from the 
standard curve (Figure 6).
In the original study, it was shown that excess GBA (i.e. GBA not accounted for by 
endogenous GCs) can be measured in paediatric patients receiving inhaled steroid therapy 
for asthma (Raivio et al. 2002). In addition, the assay was able to differentiate between 
transactivation potentials of synthetic GCs, detecting lowest bioactivity appropriately for 
cortisol, followed in rising order by methylprednisolone and dexamethasone (Raivio et al. 
2002). Mifepristone, in contrast, blocked the glucocorticoid-induced response (Raivio et al. 
2002).
GBA has also been shown to be elevated in preterm infants receiving antenatal 
glucocorticoid treatment (Kajantie et al. 2004, Nykänen et al. 2007). In contrast, in women 
receiving mifepristone for emergency post-coital contraception or for the termination of 
pregnancy, the GBA levels were reported to be subnormal (Leminen et al. 2005, Heikinheimo 
et al. 2003). In paediatric renal transplant patients, GBA was suggested to associate 
positively with excessive weight gain (Seikku et al. 2006). Recently, in infants born small 
for gestational age, the GBA levels associated with an insulin-resistant state (HOMA-IR) 
and low adiponectin levels (Tenhola et al. 2009).
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A 10 µl serum sample is added
to a COS-1 cell culture
in which the cells are 
transfected to express 
- glucocorticoid receptor
- coactivator ARIP3
- luciferase reporter
The cells are incubated overnight.
The following morning the cells are 
lysed, the relative luciferase activity is 
measured
and the glucocorticoid bioactivity 
is calculated from the standard 
curve. The higher the luciferase 
activity, the higher the GBA.
Figure 6 Schematic representation of the GbA measurement.
4.4 Glucocorticoid-sensitive biomarkers
The GC-responsive biomarkers analyzed in this study were selected to mirror GC effects 
in different tissues that are either involved in the development of common GC-related 
side effects during systemic GC therapy or reflect therapeutic response to steroid therapy 
in IBD patients. Therefore, biomarkers originating from adipose tissue and bone and 
reflecting glucose homeostasis and inflammation were measured.
4.4.1 Adiponectin
Adiponectin is a 30 kDa adipokine that is secreted mainly from adipocytes (Liu and Liu 
2010). In serum, its concentration is remarkably high (10-30 µg/ml) and it circulates in 
three forms: in low-molecular weight trimer, hexamer and a high-molecular weight 
species (Liu and Liu 2010). Adiponectin increases insulin sensitivity, suppresses hepatic 
gluconeogenesis and stimulates fatty acid oxidation (Liu et Liu 2010). It possesses anti-
inflammatory and anti-atherogenic properties and has a protective role against chronic 
inflammation (Fantuzzi 2005, Beltowski 2003). Factors known to control circulating adiponectin 
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levels are presented in Table 10. The promoter region of adiponectin gene contains GR 
binding sequence; however studies on GC effect on adiponectin levels have arrived at 
contradicting results (Takahashi et al. 2000, Halleux et al. 2001, Fasshauer et al. 2002, Uchida et al. 
2006, Weigert et al. 2009, Rieth et al. 2009). 
4.4.2 leptin
Leptin is an adipose tissue-derived hormone that is secreted in direct proportion to amount 
body fat (Friedman et al. 1998, Kelesidis et al. 2010). The circulating leptin levels reflect the body 
energy reservoir and thereby control the regulation of energy homeostasis, metabolism and 
neuroendocrine function (Kelesidis et al. 2010). In addition, leptin has been reported to have pro-
inflammatory properties (La Cava and Matarese 2004). GCs augment leptin levels, other regulating 
factors are presented in Table 10. 
4.4.3 PiNP and iCTP
Type I collagen is the main component of bone organic matrix (Calvo et al. 1996). Circulating 
amino-terminal type I procollagen propeptide (PINP) and carboxyterminal telopeptide of 
type I collagen (ICTP) measure type I collagen formation and resorption, respectively 
(Melkko et al. 1996, Risteli et al. 1993). Serum PINP and ICTP levels are affected by factors 
that control bone metabolism and their levels are related to growth velocity in healthy 
children and in children with growth disorders (Trivedi et al. 1991, Hyams et al. 1988). 
4.4.4 SHbG
Sex hormone-binding globulin (SHBG) binds estrogen and testosterone with high 
affinity and is the main transporter of sex steroids in human plasma (Pugeat et al. 2010). It 
is synthesized in the liver where hormonal, metabolic and nutritional factors affect its 
expression (Table 10). SHBG has been postulated as an independent predictor of bone 
turnover rate (Välimäki et al. 2004). In vivo, GCs have been shown to decrease SHBG levels, 
however in vitro the results have been inconsistent (Pugeat et al. 2010). 
4.4.5 iGF-i 
Insulin-like growth factor I (IGF-I) is essential for longitudinal growth and the 
maintenance of adult bone mass (Gazzerro and Canalis 2006). IGF-I circulates as a part of 
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a 150 kDa complex associated with IGF-binding protein (IGFBP)-3 or IGFBP-5 and 
acid labile subunit (Canalis 2009). IGF-I acts both as a circulating hormone and as a local 
growth factor and its expression is regulated by GH and a number of other factors (Table 
10, Gazzerro and Canalis 2006). GCs decrease the IGF-1 expression in the liver, affect the 
synthesis of the IGFBPs and suppress effects of IGF-1 in the local microenvironments 
(Canalis 2005).
4.4.6 Hs-CrP
C-reactive protein (CRP) was discovered in the 1930 (Bajpai 2009). It is an acute phase 
protein produced in the liver in response to numerous cytokines and is at present used 
as a marker of inflammation, infection and tissue injury in many diseases, including 
IBD. In paediatric IBD however, the standard CRP measurement fails to identify patients 
with active inflammation (Beattie et al. 1995). High-sensitivity CRP (hs-CRP) measures 
CRP levels that were previously thought to be under the detection limit (Bajpai 2009). 
In different conditions (cardiovascular disease, asthma) it is considered as a marker of 
disease risk or severity (Qian et al. 2008, Bajpai et al. 2009). In paediatric IBD, hs-CRP levels 
have not been investigated.
4.4.7 HbA
1C
Glycated haemoglobin (HbA1C) is employed in the follow-up of children and adolescents 
with diabetes (Zeitler et al. 2009, Koenig et al. 1976, Saudek et al. 2006). It conveys information 
on the long-term chronic glycaemic levels in the circulation and correlates with the risk 
of diabetes complications (International Expert Committee). In children receiving low dose 
inhaled GCs, HbA1C levels have been reported to be increased (Yucel et al. 2009). 
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Table 10 Factors that regulate circulating levels of adiponectin (Cook and Semple 2010, Galic et 
al. 2010, liu and liu 2010), leptin (Kelesidis et al. 2010), iGF-1 (Clayton and Hall 2004, 
rajpathak et al.2009) and SHbG (Tiitinen 2009, Pugeat et al. 2010). 
leptin Adiponectin
Overfeeding ↑ weight loss                ↑
Obesity ↑ Thiazolidinediones    ↑
Glucose ↑ Obesity     ↓
insulin ↑ insulin resistance       ↓
Glucocorticoids ↑ inflammation      ↓
estrogens ↑ Testosterone ↓
Fasting ↓ Hypoxia         ↓
leanness ↓
Thyroid hormones ↓
Androgens ↓
PPArγ agonists ↓
iGF-1 SHbG
Growth hormone ↑ Hereditary factors ↑
Undernutrition ↓ Hyperthyreosis ↑
inflammation ↓ estrogens ↑
Glucose intolerance ↓ Androgens ↓
Age, gender, pubertal status ↔ insulin resistance ↓
liver and renal function ↔ Monosaccharides ↓
ethnicity ↔
Hereditary factors ↔
Testosterone, estradiol ↔
Thyroid hormone ↔
Cortisol ↔
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AiMS OF THe STUdy
The major aim of this study was to evaluate whether GC treatment could be optimized 
by monitoring GbA and/or GC-responsive biomarkers in paediatric patients with 
inflammatory bowel disease in order to obtain the best possible therapeutic effect from 
the steroids with the least possible side-effects. 
The specific aims were:
I to study circulating serum GBA during systemic glucocorticoid treatment in children 
and adolescents with IBD.
II to evaluate the possibility of using adipose tissue-derived circulating hormones 
together with serum GBA measurement in monitoring paediatric IBD patients 
receiving glucocorticoid therapy.
 
III to assess the effect of systemic glucocorticoid treatment on markers reflecting bone 
turnover and metabolism and contrast these findings to circulating GBA in children 
with active IBD. 
IV to investigate whether the serum levels of high-sensitivity C-reactive protein could aid 
the assessment of disease activity and glucocorticoid response in paediatric patients 
with IBD.
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PATieNTS ANd MeTHOdS
1. Study subjects
1.1 Patients with inflammatory bowel disease 
The patients with inflammatory bowel disease were collected prospectively from the 
Outpatient Clinics for Paediatric Gastroenterology at the University Hospitals of Helsinki 
and Tampere. The diagnosis of IBD was based on standard clinical, endoscopical and 
histological criteria (Lennard-Jones 1989). A total of 69 patients (male 43, female 26) 
participated in the studies (Table 11). In studies I-III, all the patients were from the original 
cohort of 24 patients. From this original cohort, 22 patients were selected to study I, 19 
patients to study II, 22 patients to study III and 16 patients to study IV. In study IV, an 
additional 6 patients were collected into the prospective extension of the study. In study 
IV, a separate group of 39 IBD patients was also analyzed retrospectively.
Table 11 Patients that participated in the studies i-iv. in bold, the additional 6 patients collected to 
study iv.
Study UC Cd iC remission controls Other controls
i 18 3 1 41 101
ii 16 2 1 - -
iii 19 3  - 22 -
iv original cohort 12 3 + 5  1 + 1 - -
retrospective cohort 19  20  - - 33
         
Patients that started the glucocorticoid therapy due to the exacerbation of the disease 
received either peroral prednisolone (1 mg/kg/d, Prednisolone, Leiras, Finland, n=21), 
or budesonide (9mg/d, Entocort, AstraZeneca, Sweden, n=3) according to the clinician’s 
decision. After two weeks of treatment, tapering of the steroid dose was initiated 
following standard clinical practice (Rufo and Bousvaros 2006). Depending on the severity of 
the disease, the first clinical control was scheduled either 2 or 4 weeks after the onset of 
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the glucocorticoid. Thereafter, the controls took place at 2 to 4 week intervals. During the 
control visits, response to treatment and the appearance of glucocorticoid-related side-
effects were registered, and a venous blood sample was drawn. At the time of the study, 
no paediatric index for the activity of UC yet existed. Therefore the response to treatment 
was defined as 1) physician’s global assessment (PGA) of clinical improvement, and 
2) decrease in the inflammatory markers faecal calprotectin and ESR (Turner et al. 2010a). 
The response to treatment and the appearance of glucocorticoid-related side-effects 
(development of moon-face, weight gain, acne or striae) were graded with two-graded 
scales: good/poor response, yes/no side-effects.
The 39 patients in the study IV were consecutive paediatric IBD patients that underwent 
colonoscopy in the Hospital for Children and Adolescents, Helsinki, Finland. Colonoscopy 
was performed either to confirm the diagnosis of IBD or to assess the activity of the disease. 
For all patients taking part in the study IV, exclusion criteria were 1) previous surgery, 2) 
any signs of infection during the preceding week.
All of the patients in whom diagnosis was not fresh received conventional IBD 
medication, depending on the disease severity. These included 5-ASA products, azathioprine, 
antibiotics and infliximab. 
1.2 Control patients
We included two control groups: disease controls in remission (I, III), and non-IBD controls 
(I, IV).
1.2.1 disease controls in remission
Remission controls were 41 paediatric patients with IBD in clinical remission (median 
age 14 years, age range 4.4 to 18 years). Their maintenance medication included 5-
ASA products, and in some patients azathioprine. None of these patients had received 
glucocorticoids during the preceding month. In study I, the whole group was used as 
a control group. In study III, 22 age, sex, pubertal status and disease subtype-matched 
controls were selected from the 41 remission controls.
1.2.2 Non-ibd controls
101 paediatric patients (mean age, 8.2 years, age range 0.9 to 17 years) that visited the 
Outpatient Clinic in the Hospital for Children and Adolescents formed the other control 
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group. None of these patients had IBD, and none of these patients received glucocorticoids. 
In study I, all of the control patients were used. In study IV, 33 patients that matched the 
age and sex of the study patients were chosen from the total group of non-IBD controls 
to form a smaller control group.
2. Study design
The studies I, II, III and part of study IV were prospective non-randomized follow-up 
studies. Their design is visualized in Figure 7.
Entrance to the study:
Active ibd that 
required systematic 
glucocorticoid treatment
First clinical control
after 2-4 weeks of 
treatment depending on 
the disease severity
Control visits
at one month 
intervals
Exit from the study:
remission and 
withdrawal of the 
glucocorticoid
Time
First venous 
blood sample
Onset of the 
glucocorticoid
Second blood 
sample
Tapering of the...  ...the glucocorticoid
blood samples at 
every control visit
last blood sample 
one month after the 
discontinuation of the 
glucocorticoid
Figure 7 The design of the studies i-iv. The tapering of the steroid was started after two weeks from 
the onset of the glucocorticoid.
In study IV, an additional retrospective cross-sectional cohort of 39 paediatric IBD 
patients was analyzed at the time of the colonoscopy (Table I, IV).
3. Ethical considerations
The study protocol was approved by the Ethics Committee for the Hospital for Children 
and Adolescents, University of Helsinki, and the Ethics Committee of Tampere University 
Hospital, Tampere, Finland. The patients and their guardians were thoroughly informed 
about the studies, and a written informed consent was signed by both.
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4. Methods
4.1 Glucocorticoid-responsive biomarkers 
Table 12 GC-responsive biomarkers analyzed in the present study.
Origin Biomarker Type Properties
Adipose tissue Adiponectin Hormone A newly identified adipokine with anti-
inflammatory, anti-atherogenic and insulin-
sensitizing properties (Fantuzzi 2005, 
beltowski 2003, lihn et al. 2005).
leptin Hormone Adipose tissue-derived hormone that 
functions in the control of food intake and 
energy homeostasis (Friedman et al. 1998). 
leptin has also been reported to have  pro-
inflammatory properties (la Cava and 
Matarese 2004)
red blood cells GHbA
1C
Glycated 
haemoglobin
reflects chronic glycemic levels (The 
international expert Committee 2009).
bone PiNP Type i collagen 
formation product
A marker of bone formation  
(Melkko et al. 1996).
iCTP Type i collagen 
resorption product
A marker of bone resorption  
(risteli et al. 1993).
liver iGF-1 Hormone Mediates GH actions (walters et al. 2009).
SHbG Sex hormone-
binding globulin
Transporter of sex hormones, has been 
postulated as an independent predictor of 
bone turnover rate (välimäki et al. 2004)
Hs-CrP Acute phase protein Measures low-grade inflammation  
(Kushner et al. 2006).
4.2 Laboratory analyses
Venous blood samples were collected between 11 a.m. and 3 p.m. The analyses of standard 
laboratory tests performed in a clinical laboratory comprised erythrocyte sedimentation 
rate (ESR), blood count, standard C-reactive protein (CRP) and GHbA1C. The other 
serological markers used in the original publications are presented in Table 13. Faecal 
calprotectin was measured with an enzyme immunoassay (Phical Test, Calpro AS, Oslo, 
Norway). 
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Table 13 Serological markers used in original studies i-iv
Study Test Assay Manufacturer
Intra-
assay 
C.V.
Inter-
assay 
C.V.
Performer
I Cortisol
immulite 2000 cortisol 
kit 
diagnostic Products 
Corporation, los 
Angeles, CA
< 7.4% < 9.5%
Clinical 
laboratory
II
Adi-
ponectin
Quantikine Human 
Adiponectin iA
r&d Systems, 
Minneapolis, MN
< 4.7% < 6.9%
Professor Sture 
Andersson’s 
laboratory
II leptin
linco research Human 
leptin riA Kit
linco research, St 
Charles, MO
< 8.3% < 8.3%
Clinical 
laboratory
III PiNP UniQ riA
Orion diagnostica, 
espoo, Finland
< 10.2% < 10.2%
Clinical 
laboratory
III iCTP UniQ riA
Orion diagnostica, 
espoo, Finland
< 9.4% < 9.4%
Clinical 
laboratory
III
SHbG
AutodelFiA SHbG kit
AutodelFiA, wallac, 
Turku, Finland
< 1.8% < 10.1%
Clinical 
laboratory
III
iGF-1 iMMUliTe 2000 
analyzer
dPC, los Angeles, 
CA
nd < 4%
Clinical 
laboratory
IV hs-CrP
Human C-reactive 
protein instant eliSA kit
bender MedSystems, 
vienna, Austria
6.9 % 13.1% Author
4.3 Measurement of the glucocorticoid bioactivity (GBA) 
The GBA assay is described in more detail in the review of the literature. The amount 
of serum used by the bioassay is 10 µl, in duplicate and the results are expressed as 
nanomolar cortisol equivalents. Cortisol equivalent here means the concentration of 
cortisol in charcoal-stripped fetal calf serum that induces the same amount of reporter 
gene activity as a sample with unknown GBA (Raivio et al. 2002). The detection limit of the 
assay is 15.6 nM cortisol, within-assay coefficient of variation (C.V.) for human serum 
<8% and inter-assay variation 10%. 
4.4 Assessment of the histological activity of colonic inflammation
In study IV, the histological activity of the colonic inflammation was assessed by an 
experienced paediatric gastro-intestinal pathologist using a grading system originally 
developed for CD (D’Haens et al. 1998, Sipponen et al. 2008).
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4.5 Statistics
All statistical analyses were carried out with SPSS versions 13.0-17.0 by SPSS Inc. 
software. Associations between non-parametric variables were tested with Mann-
Whitney’s U test, Kruskal-Wallis test, Spearman’s rank order correlation test and 
Wilcoxon’s signed rank sum test. P value of <0.05 was accepted to indicate statistical 
significance.
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reSUlTS
1. Circulating GBA in paediatric patients with IBD (I)
1.1 GBA in the control patients – defining the reference value for GBA
The mean GBA level of the 142 control patients (41 paediatric IBD patients in remission 
and 101 non-IBD patients) was 61.6 nM cortisol equivalents. By adding two standard 
deviations (28 nM cortisol equivalents) to the mean, an upper limit of 118 nM cortisol 
equivalents for endogenous GBA was defined. The GBA showed strong (r=0.712, 
P<0.001, n=38) correlation with serum cortisol in the 41 paediatric IBD patients in 
remission (Figure 8).
Figure 8 The correlation between serum cortisol and GbA levels in paediatric ibd patients in 
remission.
1.2 GBA levels in paediatric IBD during glucocorticoid treatment
Before treatment was started, the GBA levels of the 22 patients from the original cohort 
were similar to controls (84 ± 14 nM cortisol equivalents, mean ± SE, P=NS).
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1.2.1 Patients treated with prednisolone
Patients treated with prednisolone (n=19) showed a significant increase in their GBA 
levels (4-fold increase at two weeks of therapy, Figure 1A, I) that persisted until the 
withdrawal of the steroid despite lowering doses of GC. GBA correlated with the time 
that had passed from the GC dose (r=-0.618, P<0.001, n=17) but not with the dose (Figure 
1B, I). Young patients (under 10 years of age, n=4) received higher weight-adjusted doses 
of prednisolone than older patients (1.3 vs. 0.79 mg/kg, P<0.05); however, their GBA 
levels were similar to the older patients (Figure 3, I). After the prednisolone treatment, 
the GBA levels of the patients decreased to values that prevailed before therapy (51.2 ± 
5.4 nM cortisol equivalents, P=NS). 
1.2.2 Patients treated with budesonide
Three patients that started the therapy with budesonide showed less increase in their GBA 
levels after 4 weeks of treatment (151 ± 20 nM cortisol equivalents) when compared to 
patients treated with prednisolone (267 ± 21 nM cortisol equivalents) (Figure 9). Two of 
these patients were later switched to prednisolone that induced a 3-fold increase in their 
GBA levels (Figure 9). 
1.2.3 GbA and glucocorticoid-related side effects
10/22 patients presented with acute (presenting during the first month of treatment) 
glucocorticoid-related side effects (rounding of the cheeks in all, steroid acne in 4). In 
addition, one girl developed increased ocular pressure after two months of treatment (late 
side-effect). The GBA levels did not predict or associate with the development of these side-
effects. At the beginning of the study, parameters such as serum glycosylated haemoglobin 
(GHbA1C), ACTH and blood pressure were followed-up (Figure 10). However, no change 
was observed in these variables during the first months of glucocorticoid treatment and 
their follow-up was ended. Budesonide-treated patients did not present with visible side-
effects.
1.2.4 GbA and disease activity
Markers of inflammation, faecal calprotectin and ESR, decreased during the glucocorticoid 
therapy; however, their levels did not associate with the GBA before, during or after the therapy 
(I). Clinical response after 4 weeks of therapy did not associate with the GBA levels.
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Figure 9 The GbA levels in two children with ibd treated with peroral prednisolone (dashed line) 
and budesonide (continuous line). The grey area underlines the difference in the GbA 
levels between these two GCs. After week four, the child treated with budesonide was also 
switched to prednisolone. dotted line, the upper normal limit for endogenous serum GbA. 
Figure 10 GHbA
1C
-levels of the 22 paediatric ibd patients during the first 6 weeks of systemic 
glucocorticoid therapy. 
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2. Adipokines during glucocorticoid treatment (II)
GC treatment increased the levels of adipose tissue-derived hormones, adiponectin (from 
11.9 ± 1.5 µg/ml to 18.7 ± 1.8 µg/ml, P<0.01) and leptin (from 4.4 ± 0.9 µg/l to 7.7 ± 1.5 
µg/l, P<0.01) after 2 (n=15) to 4 (n=3) weeks of treatment. Circulating GBA increased 
accordingly (from 86 ± 16 to 288 ± 33 nM cortisol equivalents). 
The adiponectin levels were higher in 7 patients (3 boys, 4 girls) that developed 
acute GC-related side-effects (rounding of the cheeks in all and acne in 4) than in the 11 
patients who did not (22.9 ± 2.6 µg/ml vs. 16.0 ± 2.1 µg/ml, P<0.05, Figure 11) after 2 to 
4 weeks of treatment. Serum leptin levels showed a similar trend; however, the difference 
did not reach statistical significance (11.0 ± 3.1 µg/l in patients with side-effects vs. 5.5 
± 1.2 µg/l in patients without side effects, P=0.15). 
The GBA levels, weight gain and erythrocyte sedimentation rate at 2 to 4 weeks of 
treatment were similar between the subgroups with and without side-effects (II). The 
pretreatment adiponectin levels were also similar between these two groups (side-effects, 
12.4 ± 1.5 µg/ml, no side-effects, 11.5 ± 2.5 µg/ml). The adiponectin levels at weeks 2 
to 4 were similar between patients with different diagnosis (Crohn’s disease or ulcerative 
colitis), treatment regimen (prednisolone or budesonide), therapeutic response, and sex 
(II).
Figure 11 Serum adiponectin levels before and during GC treatment in 18 paediatric  patients with 
ibd. Grey circles, patients without GC side-effects; black squares, patients with side-effects; 
horizontal line, mean (modified from ii). 
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3. Markers of bone turnover during glucocorticoid treatment (III)
The bone markers were measured in 22 paediatric patients with active IBD; the control 
patients in this study were 22 age-, sex-, Tanner stage- and disease subtype-matched 
paediatric IBD patients in remission.
3.1 Markers reflecting bone formation (PINP) and resorption (ICTP) 
Before GC therapy, the PINP levels were lower in IBD patients with active disease than 
in IBD patients with disease in remission (P<0.05). The levels of PINP and ICTP before, 
during, and after the steroid therapy are presented in Figure 12 and Table 14. 
Before treatment, PINP correlated positively with ICTP (r=0.459, n=22, p<0.05) 
and SHBG (r=0.438, n=22, p<0.05), and negatively with faecal calprotectin (r=-0.550, 
n=15, p<0.05) and ESR (r=-0.672, n=20, p<0.01). During treatment, no association was 
found between PINP, ICTP, GBA or the inflammatory markers. The development of 
glucocorticoid-related side-effects or response to treatment were not related to the PINP, 
ICTP or GBA levels before, during or after the therapy nor to the change of these markers 
during treatment (P=NS). The PINP and ICTP levels were similar between patients at 
different pubertal stages or disease subtype (III).
3.2 Markers reflecting bone metabolism and GH actions (SHBG and IGF-I)
The serum IGF-I and SHBG levels before and during GC treatment can be found in 
Figure 12 and Table 14. 
Before treatment, IGF-I correlated negatively with serum SHBG (r=-0.585, n=22, 
p<0.01) but did not associate with PINP or ICTP. Pubertal stage affected the IGF-1 levels; 
patients in Tanner stage IV-V had 3.5-fold higher IGF-1 levels than prepubertal patients 
(III). Weight, height and BMI of the patients correlated with the IGF-1 and SHBG levels; 
however, markers of disease activity (ESR, faecal calprotectin) were not related to their 
levels before or during GC therapy. Serum GBA levels, response to glucocorticoid 
treatment or the development of glucocorticoid-related side-effects did not correlate with 
serum IGF-1 or SHBG.   
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Table 14 The serum levels of PiNP, iCTP, iGF-1 and SHbG before, during, and after glucocorticoid 
therapy in 22 paediatric patients with active ibd and in 22 age-, sex-,  disease subtype- and 
pubertal stage-matched control patients with ibd in remission (iii, modified from vihinen 
et al. 2008). # p<0.05 (compared with controls); *p<0.05 (compared with pre-treatment 
levels); *** p<0.001 (compared with pre-treatment levels). 
S-PINP, µg/l S-ICTP, µg/l S-IGF-1, nmol/l S-SHBG, nmol/l
Median range Median range Median range Median range
Active IBD
Pre-
treatment
271# 88 – 849 14.2 7.6 – 26.3 23# 3 – 37 54 22 - 180
2 weeks 163*** 29 – 472 9.6*** 5.2 – 16.4 37*** 21 – 85 35*** 14 – 84
5 weeks 152*** 23 – 393 8.2*** 5.5 – 16.7 37*** 3 – 72 28*** 11 – 108
1 month after 
treatment
516*/NS 143 – 909 18.7*/NS 10.1 – 24.9 27*/NS 16 – 50 66/NS 22 – 179
Controls 535 111 – 1390 14.7 8.8 – 28 29 13 – 54 87 15 – 167
Figure 12 Serum PiNP (X), iCTP (▲), iGF-1 (●) and SHbG (■) in 22 paediatric patients with 
active inflammatory bowel disease before, during, and after treatment with systemic 
glucocorticoids.
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4. High sensitivity C-reactive protein (hs-CRP) in paediatric IBD (IV)
4.1 Hs-CRP during glucocorticoid treatment 
59% (13/22) of the patients with active IBD presented with undetectable (<5 mg/L) 
standard CRP levels, and their hs-CRP levels were measured. Of these patients, 7 children 
showed a good response to GC therapy. However, the change in the hs-CRP levels during 
steroid treatment was similar between patients that responded to the therapy and in non-
responders (P=0.16) (Figure 13). The pretreatment hs-CRP levels were similar between 
responders (median, 0.3 mg/L, range 0.05-1.7) and non-responders (0.1 mg/L, 0.01-0.6, 
P=NS) and did not predict the treatment outcome (unpublished results). The development 
of glucocorticoid-related side-effects did not associate with serum CRP levels.
Figure 13 The hs-CrP levels in GC treatment responders (continuous line) and non-responders 
(dashed line) in 13 children with active ibd.
4.2 Hs-CRP levels related to intestinal inflammation
In retrospective analysis, 64% (25/39) of the paediatric IBD patients investigated at the 
time of the colonoscopy had undetectable standard CRP levels. The median CRP level of 
the patients was 0.4 mg/L (0.007 – 45 mg/L), significantly higher than in the 33 control 
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patients (0.03 mg/L, 0.008-0.7 mg/L, P<0.001). Hs-CRP was measurable in all cases 
with undetectable standard CRP (25/39) and higher than in the control patients (P<0.01, 
unpublished results), but could not sort the patients according to disease activity (active 
disease 0.2 mg/L, 0.007-1.37, n=17 vs. quiescent disease 0.1 mg/L, 0.01-1.89, n=8, 
P=NS). Children with ileocolonic CD had significantly higher CRP levels (14 mg/L, 
0.06-45, n=13) than patients with CD colitis (0.18 mg/L, 0.01-9, n=7, P<0.01) or UC 
(0.13 mg/L, 0.007-23, P=NS). The CD patients presenting with granulomas had clearly 
higher CRP levels (14 mg/L, 0.5-39, n=9) than patients without granulomas (0.5 mg/L, 
0.01-45, n=11, P<0.05). The levels of CRP, faecal calprotectin, ESR and WBC in these 
patients are presented in Table 15 according to disease activity. CRP only correlated with 
the histological activity of the inflammation in the ileum (IV).
Table 15 The CrP, faecal calprotectin, eSr and wbC levels in 39 paediatric  
patients treated with systemic GCs. * p<0.05; ** p<0.01.
     CRP, mg/L Calprotectin, µg/g  ESR, mm/h WBC, E9/L
Active disease
yes 0.7, 0.007-45 1030, 14-4400 22, 2-97 7.8, 3.2-17.4
No 0.1, 0.01–12* 180, 24-1010* 5, 4-14** 6.6, 4.3-8.6
Fresh diagnosis
yes 0.7, 0.02-39 1040, 26-4400 26, 2-97 8.0, 3.2-17.0
No 0.2, 0.007-45 610, 14-2010 12, 4-33** 7.0, 3.9-17.4
5. Summary of the results of GC-responsive biomarkers
Table 16 direction of change of the GC-responsive biomarkers during GC-therapy in paediatric 
patients with ibd.
Origin biomarker direction of change 
Adipose tissue Adiponectin ↑
leptin ↑
bone PiNP ↓
iCTP ↓
liver iGF-1 ↑
SHbG ↓
Hs-CrP ↓
red blood cells GHbA
1C
↔
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diSCUSSiON
Systemic GC therapy is used worldwide in the treatment of diverse inflammatory and 
immune disorders. In IBD, the majority of the patients benefit from the treatment, however 
around 30% of the patients are resistant to the therapy. In addition, the development of 
the GC treatment-related side-effects is common. A measurement that could identify the 
possible responders from non-responders and the patients who are susceptible to serious 
side-effects would be vital. At present, we have no method in clinical practice with 
which to predict the individual’s response to treatment in advance. Therefore, the aim 
of this study was to identify biomarkers originating from different tissues, and evaluate 
the possibility of using the GBA measurement as an aid in recognizing GC-responsive 
patients during systemic steroid therapy in children and adolescents with IBD.
1. Glucocorticoid bioactivity during glucocorticoid treatment (I)
In the first study, the aim was to assess whether the GBA measurement could direct the 
steroid therapy in children and adolescents with IBD.
In this study, the GBA was measurable in all patients, and as in other studies correlated 
strongly with serum cortisol before the treatment was started, showing high internal 
validity of the assay (Raivio et al. 2002, Heikinheimo et al. 2003, Nykänen et al. 2007). Regrettably 
however, the GBA levels did not associate with the clinical response to GCs (therapeutic 
response or the development of GC-related side-effects) during systemic GC treatment 
in paediatric IBD patients. Thus, in the light of these results, the GBA cannot be used as 
a tool to optimize steroid therapy in children with IBD. The findings are in accordance 
with those of a recent Canadian study which reported no association between GBA and 
GC-response in 50 paediatric patients treated with intravenous GCs for acute severe UC 
(Turner et al. 2010b). However, the assay has been reported to differentiate appropriately 
between different biopotencies of synthetic steroids in this and other studies, and to be 
blocked by a GC antagonist/partial agonist mifepristone (Raivio et al. 2002, Heikinheimo et al. 
2003, Leminen et al. 2005). Therefore, the assay should reliably reflect the circulating GBA, 
and other factors that could explain the results will be discussed. 
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1.1 Factors that could have affected the GBA measurement
1.1.1 GC absorption, dose and timing
Factors that could have affected the GBA results in this study are the absorption of the 
administered GCs, as well as the steroid dose and the time that had elapsed from the GC. 
As previously stated, the absorption of prednisolone in active IBD is considered to be 
normal (Olivesi 1985, Faure et al. 1998, Schwab et al. 2001). In this study, the steroid dose did 
not correlate with the GBA levels, and minor differences in the absorption of the drug 
that could have influenced the results cannot be ruled out. However, time that had passed 
from ingesting the previous GC dose correlated strongly with the GBA, and might have 
masked the relationship between the dose and the GBA. Due to the small sample size, 
we were unfortunately unable to test this hypothesis with logistic regression. However, 
the Canadian group which bypassed the question of variable absorption by administering 
the steroids intravenously arrived at similar conclusions as us (Turner et al. 2010b). They 
performed multivariate regression analysis adjusted for dose and the time from the last 
GC in a large group of patients, and confirmed our findings of no association between the 
GBA levels and the clinical response to GCs. 
1.1.2 Assay properties
A potential technical factor within the assay that could have influenced the GBA results is 
the 10-fold dilution of the serum samples in cell culture medium. Dilution of this kind can 
break the weakest steroid-CBG complexes and affect the GBA levels (Dunn et al. 1981). The 
affinity of prednisolone to CBG is reported to be almost as strong as that of cortisol, and 
all studies that have employed the GBA assay have reported strong correlation between 
serum cortisol and GBA (Pugeat et al. 1981). However, the possibility that the dilution of the 
samples may have influenced the GBA measurement cannot be overruled.  
Another explanation for the disconnection between the GBA results and clinical 
response to GCs stems from the general principle of the assay. The GBA assay measures 
GR-driven transactivation. Previously it was thought that the majority of the anti-
inflammatory effects of GCs are mediated via transrepression, and the side-effects 
are arbitrated by transactivation. However, recent studies have reported that there are 
actually a number of genes with a distinct anti-inflammatory profile up-regulated by GR 
(De Bosscher and Haegeman 2009). The expression of IL-10 for example, an anti-inflammatory 
and immunosuppressive cytokine important in the development of IBD, has been 
recently reported to be induced by GR, possibly by transactivation (Mayer 2010, Clark et al. 
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2007).	In	addition,	the	inhibitor	of	NFκB	α	(IκBα),	another	important	anti-inflammatory	
mediator in IBD, is up-regulated by GCs (Clark et al. 2007). Therefore, it is today considered 
that for a single wanted or unwanted GC effect there is probably a host of GC-induced 
mechanisms, positive and negative, genomic and non-genomic, that depend on the cellular 
environment and activation status and lead to various expression of a given effect in 
different situations (Clark et al. 2007).  That said however, we cannot exclude the possibility 
that the end-points we looked at in this study (therapeutic response, the development 
of GC-related side-effects) were mainly mediated by some mechanism other than GR 
induced transactivation.
1.2 GBA and GC sensitivity
Compared to adults, the GC doses of 1-2 mg mg/kg/day of prednisolone equivalents 
administered to paediatric IBD patients at the beginning of the therapy are relatively high. 
The circulating GBA levels induced by doses like this are clearly supraphysiological, 
as shown in this study by the 5-fold rise in the GBA levels after 2 weeks of treatment 
with prednisolone. However, both we and the Canadian group were unable to show any 
difference between the GBA levels in the patients who responded to GCs, and in those 
who did not (I, Turner et al. 2010b). In adult patients with IBD, the increase of the steroid 
dose from 40mg to 60mg of prednisone equivalents/day has not been shown to improve 
the clinical response to the treatment (Baron et al. 1962). It may be that the doses used at 
present in the treatment of children and adolescents with moderate to severe IBD are 
more than sufficient to induce a therapeutic response, if this occurs. Therefore, one of the 
main messages of this study is that the GC sensitivity of paediatric IBD patients, defined 
as therapeutic response to GC therapy and/or the development of GC-related side-
effects, seems not to be determined by circulating GBA measured with a transactivation 
assay. Rather, it is probably the net sum of the GBA together with the tissue- and cell-
type specific expression of different GR isoforms and polymorphisms, their covalent 
modifications and interaction with other transcription factors.
2. Adiponectin as a marker of glucocorticoid sensitivity (II)
The second specific aim of the study was to assess the effect of systemic GC treatment 
on white adipose tissue (WAT) derived adipokines adiponectin and leptin, and their 
relationship to GBA and clinical response to GCs. These investigations led to one of the 
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most interesting findings of this study, namely the association of serum adiponectin with 
visible GC-treatment related side-effects at 2-4 weeks of systemic GC therapy. No such 
connection was found for serum leptin.
At present, great interest has been posed to adiponectin’s negative association with 
indices of insulin resistance and inverse correlation with fat mass (Cook and Semple 2010, 
Tenhola et al. 2010). As GCs often impair insulin actions in humans, a negative correlation 
between GCs and adiponectin could be hypothesized. However, studies on GC effect 
on adiponectin levels have arrived at controversial results. In in vitro studies, steroid 
administration has been shown to decrease adiponectin mRNA expression and adiponectin 
release (Halleux et al. 2001, Fasshauer et al. 2002, Degawa-Yamauchi et al. 2005). In vivo, exogenous 
GCs have been reported to increase adiponectin levels (Uchida et al. 2006, Weigert et al. 2009, 
Rieth et al. 2009). 
The adiponectin gene ADIPOQ contains consensus GR binding sequence on its 
promoter (Takahashi et al. 2000). Thus, in this study it is possible that the administered 
exogenous GCs affected the adiponectin levels either directly or through lowering the 
levels	of	potent	adiponectin	secretion	inhibitors	IL-6	and	TNF-α	(Swarbrick and Havel 2008). 
Further studies are needed to address this question. However, if our findings can be 
confirmed in larger patient groups, it is possible that adiponectin may aid the recognition 
of steroid sensitive patients.
3. Markers of bone turnover (III) 
The third aim of this study was to evaluate the association of serum markers of bone 
turnover and metabolism with respect to serum GBA and GC therapy. Children with 
IBD may have decreased bone mineral density (BMD) already at diagnosis, and GC 
therapy can further compromise bone health (Sylvester 2005, Walther et al. 2006, Eastell et al. 
2010). We assessed acute changes in bone turnover and metabolism by measuring serum 
levels of amino-terminal type I procollagen propeptide (PINP) reflecting bone formation, 
and carboxyterminal telopeptide of type I collagen (ICTP) reflecting bone degradation 
respectively (Melkko et al. 1996, Risteli et al. 1993). In addition, insulin-like growth factor 
1 (IGF1) and sex hormone binding globulin (SHBG) were measured for they mediate 
growth hormone (GH) actions, and SHBG has been reported to independently predict 
bone turnover rate in adults (Yakar et al. 2002, Välimäki et al. 2004).
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3.1 Markers reflecting type I collagen turnover
In this study, the marker of type I collagen formation PINP was lower in children with 
IBD compared with remission controls, even before GC treatment was started (III). PINP 
also correlated negatively with the markers of inflammation, ESR and faecal calprotectin. 
At the same time, the ICTP levels reflecting bone degradation were similar to controls. 
“Low-turnover”	 osteoporosis	 has	 been	 characterized	 as	 osteoporosis	 where	 bone	
resorption is normal and bone formation is reduced (Tilg et al. 2008). These findings suggest 
that active inflammatory process present in children and adolescents with IBD could be a 
driving	force	behind	the	development	of	this	type	of	“low-turnover”	deterioration	of	bone	
structure that can eventually lead to osteoporosis.
After two and five weeks of GC therapy, both the markers of bone formation and 
degradation declined. This is consistent with previous reports from animal and human 
studies that have shown decreased bone turnover and reductions in the age-dependent 
increases in trabecular bone mineral content, trabecular thickness, linear growth and 
cortical thickness during GC treatment (Sorva et al. 1996, Crowley et al. 1998, Ortoft et al. 1999, 
Ikeda et al. 2003, Ton et al. 2005). In addition, in this study during GC, the PINP and ICTP no 
longer correlated with each other, as they did at baseline. The processes of bone modelling 
and remodelling are coupled by osteoblast-derived RANKL and osteoprotegerin (OPG) 
(Hadjidakis and Androulakis 2006). In children treated with inhaled GCs for asthma, PINP and 
ICTP decreased similarly to this study, but the markers correlated even during the therapy 
(Sorva et al. 1996). The lack of correlation between bone formation and resorption markers 
during systemic GC treatment in this study can reflect the loss of the tight coordination 
between these two processes. Taken together, these findings do support the concept that 
despite the potential beneficial effects that GC treatment has on the bone structure by 
controlling the inflammatory process in IBD patients, it is probably still an additional risk 
factor for impaired bone quality (Eastell et al. 2010).    
After treatment, the PINP and ICTP levels rose to a level similar to the controls, 
showing that the effects of inflammation and peroral steroid therapy on bone turnover 
were reversible. The long-term impact that systemic GC treatment in childhood has on 
adult BMD and height is being debated. The theory that the peak bone mass achieved in 
young adulthood determines bone health decades later has been questioned, and studies 
show that interventions to increase BMD in all age groups seem to have only transient 
effects (Gafni et al. 2007). In addition, GC-treatment induced increased fracture risk has been 
shown to return to baseline approximately 1 year after the withdrawal of the steroid (Van 
Staa et al. 2000, Vestergaard et al. 2008). The findings of this study thus accord, in that reasonably 
high-dose (1 mg/kg/day prednisone equivalents at initiation) systemic GC treatment that 
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lasted for a moderately long period (median 6 months) did not have a persistent effect on 
bone turnover markers at one month after the therapy was withdrawn. 
3.2 Markers reflecting GH actions
At the beginning of the study, the IGF-I levels were lower in patients that had active 
disease compared with remission controls. Previous studies have yielded similar results 
(Eivindson et al. 2007, Sylvester et al. 2007). This finding probably reflects the inhibitory effect 
that	circulating	inflammatory	cytokines	such	as	TNF-α,	IL-6	and	IL-1β	have	on	the	GH-
receptor and IGF-I expression in the liver,  and might contribute to the decreased BMD 
and possible growth failure seen in patients with active IBD (Cezard et al. 2002, Sylvester et al. 
2007, Theiss et al. 2004, Eivindson et al. 2007).
During GC treatment, the IGF-I levels rose in contrast to all the other markers 
reflecting bone turnover. In earlier studies, partial normalization of IGF-I levels during GC 
treatment has been seen in IBD adults (Grønbæk et al. 2002, Eivindson et al. 2007). In addition, in 
IBD children therapeutic interventions have been shown to increase IGF-1 levels (Thomas 
et al. 1993, Beattie et al. 1998). However, in the former paediatric study, the patients treated 
with steroids displayed lower growth velocity SD score despite higher IGF-1 levels than 
patients treated with elemental diet (Thomas et al. 1993). Postulated mechanisms for this 
controversial phenomenon are GC-induced IGF-1 resistance, low IGF-1 bioactivity and 
dose-dependent effects of GCs on IGF-1 expression (Thomas et al. 1993, Dong et al. 2003, 
Grønbæk et al. 2002). 
The SHBG levels in children with active IBD were similar to controls. However, at 
baseline the SHBG correlated positively with the marker of bone formation, PINP. This 
finding, first published in young Finnish men, was very recently confirmed in a group 
of young Belgian men (Välimäki et al. 2004, Vanbillemont et al. 2010). The clinical significance 
of this result is as yet unclear, as studies on the relationship of SHBG with BMD have 
arrived at contradicting results (Lormeau et al. 2004, Vanbillemont et al. 2010). Similarly, also the 
molecular basis of this association remains elusive. However, as SHBG has been shown 
to be an independent predictor of bone turnover rate, the presence of a specific membrane 
bound receptor for SHBG has been postulated (Vanbillemont et al. 2010).
3.3 Bone turnover markers, GBA and clinical response
Regrettably, no associations were found between PINP, ICTP, IGF-1, SHBG, GBA levels, 
therapeutic response to GCs or the development of GC-related side-effects. Therefore, 
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according to the results of this study, these markers do not aid the GC treatment of 
paediatric IBD patients. A possible explanation might be that the GC effects on bone are 
mediated via mechanisms other than DNA-dependent transactivation, or the mechanisms 
responsible for GC-associated visible adverse effects. 
4. Hs-CRP in paediatric IBD (IV)
The fourth specific aim of this study was to evaluate the possibility of using hs-CRP 
in children and adolescents with IBD. In detail, to assess whether it associates either 
with the outcome of GC therapy or is related to the clinical and/or histological disease 
activity in IBD patients. Disappointingly, the answer for both of these main questions 
was negative, and the hs-CRP was found to be no more useful in the treatment of these 
patients than standard CRP testing. However, the CRP levels were higher in patients with 
CD and associated with histological activity of the inflammation in the ileum and with the 
presence of granulomas. Recently, the hs-CRP levels have been reported to associate with 
the endoscopical activity of IBD inflammation in CD adults (Jones et al. 2008). Thus, in CD, 
the CRP measurement might act as an indicator of intestinal inflammation; however, 
further studies are needed.  
In this study, it was found that the change in hs-CRP levels in children treated with 
GCs did not associate with the response to treatment. This result reinforces the concept 
that in paediatric IBD, the CRP measurement is of limited clinical value (Vermeire et al. 2006). 
However, the CRP levels in the IBD patients were higher than in healthy controls. Earlier 
this year, Dagni et al. reported that hs-CRP levels and carotid intima media thickness, 
carotid arterial stiffness, insulin resistance assessed by HOMA-IR and homocysteine 
levels were higher in adult IBD patients compared with healthy controls with a similar 
BMI. This is the first study to show that paediatric IBD patients also present with such 
low-grade inflammation. IBD that manifests during childhood can therefore be a possible 
risk factor for the development of early atherosclerosis which may increase the disease 
burden of the patients later on in life (Dagni et al. 2010, Papa et al. 2005, Ha et al. 2009).
5. Limitations of the study
One of the limitations of this study is the small number of patients, which is a common 
problem in paediatric studies. However, these studies were designed to be pilot studies 
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and the objective was to collect enough patients to obtain preliminary results of the large 
array of laboratory markers investigated. The specific findings of this thesis do need to be 
confirmed in larger patient groups, but this is the first study that approaches the question 
of GC-responsiveness by measuring GBA and biomarkers from different tissues in the 
clinical setting.    
Another possible limitation of this study is that the clinical activity indices of UC 
and CD were not included; however, at the time the study was initiated, no activity 
index existed for paediatric UC (Turner et al. 2007). Furthermore, recent studies show that 
clinical indices correlate poorly with the presence of intestinal inflammation (Sipponen et 
al. 2008). Here the assessment of disease activity was based on PGA (Physician’s Global 
Assessment).
Finally, the design of this study does limit the findings to paediatric patients with 
IBD. Therefore, the conclusions on the utility of the GBA assay cannot be generalized to 
other patient groups.
6. General discussion and future considerations
During recent years our knowledge of the GR signalling pathway has expanded, and a 
system that once might have seemed straightforward has grown into a complex web of 
associations which depend upon the prevailing conditions. At the moment we are in a 
situation where we have an enormous amount of data on newly identified GR isoforms, 
polymorphisms, signalling cofactors and interacting proteins, but no clear view of their 
significance in health and disease. Therefore, this study that combines clinical data with 
newly developed biomolecular assay and recently identified biomarkers from different 
tissues	 is	 exactly	 the	 type	of	“crossroads”	 study	 that	we	need,	 to	 step-by-step	build	a	
general picture of GR actions in different tissues.  
The main finding of this study, that systemic bioactivity of GC treatment measured 
with a transactivation assay does not associate with clinical response to steroid therapy, 
raises new prospects for future research. It seems ever more likely that the response to GC 
treatment depends on the GC sensitivity at target cell level, not on systemic bioactivity 
of a given compound. However, in IBD there is local as well as systemic activation of 
the inflammatory pathways and defining the exact culprit cell population is, at present, 
impossible.  Therefore, future studies on GR function should include both circulating 
PBMCs and colonic mucosal epithelial and inflammatory cells. An example for future 
research could be to study the presence of the BclI polymorphism in circulating PBMCs 
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in	patients	with	IBD,	and	correlate	 the	findings	with	GRα/β	expression	 in	 the	colonic	
mucosa and with the response to GC therapy (Labuda et al. 2010). 
Another novel finding of this study, the association of serum adiponectin with GC 
treatment related adverse events, warrants further studies. During the past decade, 
adipose tissue has emerged as a new endocrine organ that is actively involved in the 
control of energy homeostasis, insulin sensitivity and inflammation (Galic et al. 2010). It 
is possible that the adiponectin levels in this study reflect indirectly the decrease in the 
levels	of	adiponectin	secretion	inhibitors	TNF-α	or	IL-6.	However,	if	these	findings	can	
be confirmed in larger studies, serum adiponectin could be used as a readily available 
marker of sensitivity to GC-related adverse events.
Regrettably, in this study no correlations were found between the markers of bone 
turnover, GBA and therapeutic response to GCs. However, the present study strengthens 
the view that bone health in active paediatric IBD is compromised and systemic GC 
therapy further disturbs the balance between bone formation and resorption. In addition, 
we report that after the withdrawal of the steroid, all the bone turnover markers restore 
to levels similar to controls, showing that good response in controlling the inflammatory 
process reflects to bone health. A recent report in Cell Metabolism states that GCs might 
suppress bone formation by interfering osteoblast differentiation via monomeric GR 
(Rauch et al. 2010). It is probable that monomeric GR does not mediate its functions through 
binding to the DNA, but affects gene transcription by interacting with other transcription 
factors. If this finding is confirmed in other studies and the GR monomer emerges as the 
predominant mediator of GC effects in bone, we need new types of bioassays to evaluate 
and predict the impact of GCs on bone in the clinical setting.   
An intriguing novel finding of this study was to show that SHBG correlates with 
PINP, a marker of bone formation, before GC treatment in children with IBD. In adults, 
SHBG has been shown to correlate negatively with BMD, and high levels of SHBG 
associate with the presence of fractures (Hoppé et al. 2010). In children, the significance 
of the relationship between SHBG and bone turnover marker is as yet unclear. Whilst 
puberty affects the SHBG levels, a specific issue to be addressed in the future is the effect 
of age on this finding.
Finally, the value of measuring hs-CRP in paediatric IBD was evaluated. It was found 
that the high-sensitivity measurement of CRP does not seem to offer any advantage over 
the standard CRP testing, neither when measured at the time of the colonoscopy nor in 
monitoring GC treatment. However, the histological activity of the ileal inflammation 
associated with hs-CRP levels in CD patients, and patients with ileal disease did present 
with higher CRP levels than patients with colonic involvement only. The NOD2/CARD15 
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mutation has been associated with ileal disease location and it is tempting to speculate 
that differences in the innate immune system might alter the disease process in the ileum 
(McGreal and Cho 2008). 
In this study, the GBA levels did not associate with the response to GCs. However, 
there are clinical situations where information on the bioactivity of the circulating GCs 
would be vital. These could include for example patients in intensive care or situations 
where the immunologically analyzed cortisol levels and clinical symptoms do not 
match. 
Recently, it has been evaluated that the GR splice and translational isoforms identified 
until now can form up to 256 different homo- and heterodimers that all might express 
distinct patterns of intracellular distribution, coactivator recruitment and transactivation 
and -repression properties (Nicolaides et al. 2010). Consequently, as the system turns out be 
far more complex than expected, explaining why some patients respond to GC therapy 
while others develop only the side-effects seems to be fleeing further away. This study is 
the first attempt to open up this subject, and bring together basic and clinical research. 
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CONClUSiONS
The main results and conclusions of this study can be summarized as follows:
I The GBA levels of paediatric patients with IBD receiving systemic GCs were higher 
than in control patients with no GC therapy. However, the GBA levels did not correlate 
with clinical response or the development of GC-related side-effects and therefore do 
not seem to aid the GC therapy in these patients. 
II Adipocyte-derived adiponectin was associated with the development of GC therapy-
related adverse events. This circulating adipokine could be a potential biomarker of 
GC-sensitivity. The adiponectin levels were not related to the GBA levels.
III   Serum PINP and IGF-1 reflecting bone formation and GH actions were lower in 
patients with active IBD than in controls, probably because of the active inflammatory 
process. All the bone turnover markers changed readily in response to the onset of 
systemic GC treatment. After the withdrawal of the steroid, they restored to levels 
similar to the controls. However, the bone turnover markers were not related to the 
clinical response, the development of GC-related side effects or the GBA levels.
IV Serum hs-CRP levels were similar in patients that responded to GC treatment and in 
non-responders. In CD patients, the hs-CRP levels associated with the histological 
activity of the ileal inflammation. 
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